<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Drugs for treating Schistosoma mansoni infection - Danso‐Appiah, A - 2013 | Cochrane Library</title> <meta content="Drugs for treating Schistosoma mansoni infection - Danso‐Appiah, A - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000528.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Drugs for treating Schistosoma mansoni infection - Danso‐Appiah, A - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000528.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000528.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Drugs for treating &lt;i&gt;Schistosoma mansoni&lt;/i&gt; infection" name="citation_title"/> <meta content="Anthony Danso‐Appiah" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="tdappiah@yahoo.co.uk" name="citation_author_email"/> <meta content="Piero L Olliaro" name="citation_author"/> <meta content="World Health Organization" name="citation_author_institution"/> <meta content="Sarah Donegan" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="David Sinclair" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Jürg Utzinger" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD000528.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/02/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000528.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000528.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000528.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Commiphora; Oxamniquine [*therapeutic use]; Plant Extracts [therapeutic use]; Praziquantel [*therapeutic use]; Randomized Controlled Trials as Topic; Resins, Plant; Schistosomiasis mansoni [*drug therapy]; Schistosomicides [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000528.pub2&amp;doi=10.1002/14651858.CD000528.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000528\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000528\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pt","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000528.pub2",title:"Drugs for treating   \u003ci\u003eSchistosoma mansoni\u003c/i\u003e infection",firstPublishedDate:"Feb 28, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000528.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000528.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000528.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000528.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000528.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000528.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000528.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000528.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000528.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000528.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4221 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000528.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-sec-0146"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-sec-0030"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-sec-0031"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-sec-0140"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/table_n/CD000528StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/table_n/CD000528StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Drugs for treating <i>Schistosoma mansoni</i> infection</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information#CD000528-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Anthony Danso‐Appiah</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information#CD000528-cr-0003">Piero L Olliaro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information#CD000528-cr-0004">Sarah Donegan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information#CD000528-cr-0005">David Sinclair</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information#CD000528-cr-0006">Jürg Utzinger</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information/en#CD000528-sec-0153">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 February 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000528.pub2">https://doi.org/10.1002/14651858.CD000528.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000528-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000528-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000528-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000528-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000528-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000528-abs-0002">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000528-abs-0001" lang="en"> <section id="CD000528-sec-0001"> <h3 class="title" id="CD000528-sec-0001">Background</h3> <p><i>Schistosoma mansoni</i> is a parasitic infection common in the tropics and sub‐tropics. Chronic and advanced disease includes abdominal pain, diarrhoea, blood in the stool, liver cirrhosis, portal hypertension, and premature death. </p> </section> <section id="CD000528-sec-0002"> <h3 class="title" id="CD000528-sec-0002">Objectives</h3> <p>To evaluate the effects of antischistosomal drugs, used alone or in combination, for treating <i>S. mansoni</i> infection. </p> </section> <section id="CD000528-sec-0003"> <h3 class="title" id="CD000528-sec-0003">Search methods</h3> <p>We searched MEDLINE, EMBASE and LILACS from inception to October 2012, with no language restrictions. We also searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2012) and mRCT. The reference lists of articles were reviewed and experts were contacted for unpublished studies. </p> </section> <section id="CD000528-sec-0004"> <h3 class="title" id="CD000528-sec-0004">Selection criteria</h3> <p>Randomized controlled trials of antischistosomal drugs, used alone or in combination, versus placebo, different antischistosomal drugs, or different doses of the same antischistosomal drug for treating <i>S. mansoni</i> infection. </p> </section> <section id="CD000528-sec-0005"> <h3 class="title" id="CD000528-sec-0005">Data collection and analysis</h3> <p>One author extracted data and assessed eligibility and risk of bias in the included studies, which were independently checked by a second author. We combined dichotomous outcomes using risk ratio (RR) and continuous data weighted mean difference (WMD); we presented both with 95% confidence intervals (CI). We assessed the quality of evidence using the GRADE approach. </p> </section> <section id="CD000528-sec-0006"> <h3 class="title" id="CD000528-sec-0006">Main results</h3> <p>Fifty‐two trials enrolling 10,269 participants were included. The evidence was of moderate or low quality due to the trial methods and small numbers of included participants. </p> <p><i>Praziquantel</i> </p> <p>Compared to placebo, praziquantel 40 mg/kg probably reduces parasitological treatment failure at one month post‐treatment (RR 3.13, 95% CI 1.03 to 9.53, two trials, 414 participants, <i>moderate quality evidence</i> ). Compared to this standard dose, lower doses may be inferior (30 mg/kg: RR 1.52, 95% CI 1.15 to 2.01, three trials, 521 participants, <i>low quality evidence</i> ; 20 mg/kg: RR 2.23, 95% CI 1.64 to 3.02, two trials, 341 participants, <i>low quality evidence</i> ); and higher doses, up to 60 mg/kg, do not appear to show any advantage (four trials, 783 participants, <i>moderate quality evidence</i>). </p> <p>The absolute parasitological cure rate at one month with praziquantel 40 mg/kg varied substantially across studies, ranging from 52% in Senegal in 1993 to 92% in Brazil in 2006/2007. </p> <p><i>Oxamniquine</i> </p> <p>Compared to placebo, oxamniquine 40 mg/kg probably reduces parasitological treatment failure at three months (RR 8.74, 95% CI 3.74 to 20.43, two trials, 82 participants, <i>moderate quality evidence</i> ). Lower doses than 40 mg/kg may be inferior at one month (30 mg/kg: RR 1.78, 95% CI 1.15 to 2.75, four trials, 268 participants, <i>low quality evidence</i> ; 20 mg/kg: RR 3.78, 95% CI 2.05 to 6.99, two trials, 190 participants, <i>low quality evidence</i> ), and higher doses, such as 60 mg/kg, do not show a consistent benefit (four trials, 317 participants, <i>low quality evidence</i>). </p> <p>These trials are now over 20 years old and only limited information was provided on the study designs and methods. </p> <p><i>Praziquantel versus oxamniquine</i> </p> <p>Only one small study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg and we are uncertain which treatment is more effective in reducing parasitological failure (one trial, 33 participants, <i>very low quality evidence</i>). A further 10 trials compared oxamniquine at 20, 30 and 60 mg/kg with praziquantel 40 mg/kg and did not show any marked differences in failure rate or percent egg reduction. </p> <p><i>Combination treatments</i> </p> <p>We are uncertain whether combining praziquantel with artesunate reduces failures compared to praziquantel alone at one month (one trial, 75 participants, <i>very low quality evidence</i>). </p> <p>Two trials also compared combinations of praziquantel and oxamniquine in different doses, but did not find statistically significant differences in failure (two trials, 87 participants). </p> <p><i>Other outcomes and analyses</i> </p> <p>In trials reporting clinical improvement evaluating lower doses (20 mg/kg and 30 mg/kg) against the standard 40 mg/kg for both praziquantel or oxamniquine, no dose effect was demonstrable in resolving abdominal pain, diarrhoea, blood in stool, hepatomegaly, and splenomegaly (follow up at one, three, six, 12, and 24 months; three trials, 655 participants). </p> <p>Adverse events were not well‐reported but were mostly described as minor and transient.</p> <p>In an additional analysis of treatment failure in the treatment arm of individual studies stratified by age, failure rates with 40 mg/kg of both praziquantel and oxamniquine were higher in children. </p> </section> <section id="CD000528-sec-0007"> <h3 class="title" id="CD000528-sec-0007">Authors' conclusions</h3> <p>Praziquantel 40 mg/kg as the standard treatment for <i>S. mansoni</i> infection is consistent with the evidence. Oxamniquine, a largely discarded alternative, also appears effective. </p> <p>Further research will help find the optimal dosing regimen of both these drugs in children. </p> <p>Combination therapy, ideally with drugs with unrelated mechanisms of action and targeting the different developmental stages of the schistosomes in the human host should be pursued as an area for future research. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000528-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000528-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000528-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000528-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000528-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000528-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000528-abs-0006">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000528-abs-0005" lang="en"> <h3>Drugs for treating Schistosoma mansoni infection</h3> <p><i>Schistosoma mansoni</i> is a parasitic worm common in Africa, the Middle East and parts of South America. The worm larvae live in ponds and lakes contaminated by faeces, and can penetrate a persons’ skin when they swim or bathe. Inside the host, the larvae grow into adult worms; these produce eggs, which are excreted in the faeces. Eggs rather than worms cause disease. Long‐term infection can cause bloody diarrhoea, abdominal pains, and enlargement of the liver and spleen. </p> <p>In this review, researchers in the Cochrane Collaboration evaluated drug treatments for people infected with <i>Schistosoma mansoni</i>. After searching for all relevant studies, they found 52 trials, including 10,269 people, conducted in Africa, Brazil and the Middle East. Most trials report on whether or not the treatment stops eggs excretion; three reported the persons recovery from symptoms. </p> <p>The results show that a single dose of praziquantel (40 mg/kg), as recommended by the World Health Organization, is an effective treatment for <i>Schistosoma mansoni</i> infection. Lower doses may be less effective, and higher doses probably have no additional benefit. </p> <p>Oxamniquine (40 mg/kg), though now rarely used, is also effective. Again, lower doses may be less effective and no advantage has been demonstrated with higher doses. </p> <p>Only one study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg, and based on this limited evidence, we are uncertain which intervention is more effective. Adverse events were not well reported for either drug, but were mostly described as minor and transient. </p> <p>In children aged less than 5 years, there is limited evidence that these doses may be less effective, and further research will help optimise the dose for this age‐group. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000528-sec-0146" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000528-sec-0146"></div> <h3 class="title" id="CD000528-sec-0147">Implications for practice</h3> <section id="CD000528-sec-0147"> <p>The available evidence supports single dose praziquantel at 40 mg/kg as the standard treatment for <i>S. mansoni</i> infection as recommended by the WHO. </p> <p>Oxamniquine, a largely discarded alternative, appears efficacious and production and distribution should continue to ease selective pressure on praziquantel. However, its use should be limited to areas without <i>S. haematobium</i> co‐endemicity. </p> </section> <h3 class="title" id="CD000528-sec-0148">Implications for research</h3> <section id="CD000528-sec-0148"> <p>Further research is necessary to find the optimal dosing regimen of praziquantel and oxamniquine in children under five years, given the observational evidence that failure rates with 40 mg/kg may be higher in this age‐group. </p> <p>Combination therapy, ideally with drugs with unrelated mechanisms of action and targeting the different developmental stages of the schistosomes in the human host should be pursued as an area for future research; for example; praziquantel plus oxamniquine, praziquantel plus mefloquine, and praziquantel plus an artemisinin derivative. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000528-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000528-sec-0030"></div> <div class="table" id="CD000528-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Praziquantel 40 mg/kg for treating S. mansoni infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Praziquantel 40 mg/kg for treating <i>S. mansoni</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with <i>S. mansoni</i> infection<br/> <b>Settings:</b> Endemic settings<br/> <b>Intervention:</b> Praziquantel 40 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks<sup>1</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Praziquantel 40 mg/kg</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Parasitological failure</b> </p> <p>at 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69 per 100</b> <br/> (23 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.13</b> <br/> (1.03 to 9.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>414<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 20 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> <br/> (34 to 72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.23</b> <br/> (1.64 to 3.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 30 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> <br/> (25 to 44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.52</b> <br/> (1.15 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 60 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> <br/> (16 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/> (0.73 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>783<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus split dose</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> <br/> (3 to 37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.47</b> <br/> (0.13 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>525<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is given in the footnotes. </p> <p>The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Treatment failure with praziquantel 40 mg/kg ranged from 5% to 48% in the included studies. The risk given here is the median risk in these studies and is given for illustrative purposes.<br/> <sup>2</sup> No serious risk of bias. Both studies adequately concealed allocation and blinded participants and investigators. Loss to follow‐up was high in one study.<br/> <sup>3</sup> No serious inconsistency: Both trials showed statistically significant benefits with praziquantel but the size of the effect varied. In Kenya in 1999 failure with praziquantel was 43% at one month and in Uganda in 2009 it was 18%.<br/> <sup>4</sup> Downgraded by 1 for indirectness: Only two trials from limited settings have evaluated this comparison.<br/> <sup>5</sup> Downgraded by 1 for risk of bias: These trials are more than twenty years old and do not provide an adequate description of methods to reduce the risk of bias.<br/> <sup>6</sup> No serious risk of bias: The three trials by Olliaro in 2010 adequately concealed allocation and blinded participants and investigators to be considered at low risk of bias.<br/> <sup>7</sup> Downgraded by 1 for indirectness: The trials so far do not indicate a benefit with higher doses than 40 mg/kg. However, we cannot be certain that there might not be some benefit in specific settings.<br/> <sup>8</sup> Downgraded by 1 for inconsistency: One trial found a significant benefit with splitting the dose and one did not. The trials were of similar size and power. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000528-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oxamniquine 40 mg/kg for treating S. mansoni infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oxamniquine 40 mg/kg for treating <i>S. mansoni</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with <i>S. mansoni</i> infection<br/> <b>Settings:</b> Endemic settings<br/> <b>Intervention:</b> Oxamniquine 40 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks<sup>1</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oxamniquine 40 mg/kg</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Parasitological failure</b> </p> <p>at 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus placebo<sup>2</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 per 100</b> <br/> (66 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.74</b> <br/> (3.74 to 20.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 20 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>68 per 100</b> <br/> (37 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.78</b> <br/> (2.05 to 6.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 30 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b> <br/> (21 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> <br/> (1.15 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268</p> <p>(4 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 60 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> <br/> (2 to 38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.45</b> <br/> (0.09 to 2.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is given in the footnotes. </p> <p>The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Treatment failure with oxamniquine 40 mg/kg ranged from 5% to 24% in the included studies. The risk given here is the median risk in these studies and is given for illustrative purposes.<br/> <sup>2</sup> Parasitological failure for the comparison with placebo was only reported at three months.<br/> <sup>3</sup> Downgraded by 1 for serious risk of bias: These studies did not adequately describe any methods to reduce the risk of bias.<br/> <sup>4</sup> Only two small studies have assessed this comparison. However, due to the very large effect size we have not downgraded further for indirectness or imprecision.<br/> <sup>5</sup> Downgraded by 1 for indirectness: These studies are either too few, too small, or too old to have full confidence that the results can be generalized to widespread control of <i>S. mansoni</i> today. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000528-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Praziquantel 40 mg/kg versus oxamniquine 40 mg/kg for treating <i>S. mansoni</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> People with <i>S. mansoni</i> infection<br/> <b>Settings:</b> Endemic settings<br/> <b>Intervention:</b> Oxamniquine 40 mg/kg </p> <p><b>Control:</b> Praziquantel 40 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Praziquantel </b> </p> <p><b> 40 mg/kg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oxamniquine</b> </p> <p><b>40 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parasitological failure</b> </p> <p>at 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 100</b> <br/> (7 to 61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.40</b> <br/> (0.13 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. </p> <p>The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 for serious risk of bias: This study did not adequately describe any methods to reduce the risk of bias.<br/> <sup>2</sup> Downgraded by 1 for indirectness: This single study is over 20 years old. <br/> <sup>3</sup> Downgraded by 1 for imprecision: This trial is underpowered to detect what might be important differences in effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000528-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone for treating <i>S. mansoni</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> People with <i>S. mansoni</i> infection<br/> <b>Settings:</b> Endemic settings<br/> <b>Intervention:</b> Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) </p> <p><b>Control:</b> Praziquantel (40 mg/kg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Praziquantel </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Artesunate plus praziquantel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parasitological failure</b> </p> <p>at 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 100</b> <br/> (17 to 55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/> (0.35 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (eg the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 for serious risk of bias: This study did not adequately describe any methods to reduce the risk of bias.<br/> <sup>2</sup> Downgraded by 1 for indirectness: This is a single study and the result is not easily generalized.<br/> <sup>3</sup> Downgraded by 1 for imprecision: This trial is underpowered to detect what might be important differences in effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000528-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000528-sec-0031"></div> <section id="CD000528-sec-0032"> <h3 class="title" id="CD000528-sec-0032">Description of the condition</h3> <p>Schistosomiasis is a parasitic blood fluke infection, of which three species commonly infect humans; <i>Schistosoma mansoni</i> (common in the tropics and sub‐tropics), <i>S. haematobium</i> (mostly endemic in Africa and the Middle East) and <i>S. japonicum</i> (endemic in the People's Republic of China and the Philippines) (<a href="./references#CD000528-bbs2-0107" title="EngelsD , ChitsuloL , MontresorA , SavioliL . The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Tropica2002;82(2):139‐46. ">Engels 2002</a>; <a href="./references#CD000528-bbs2-0163" title="WHO . Prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1‐57. 2002. ">WHO 2002</a>; <a href="./references#CD000528-bbs2-0117" title="GryseelsB , PolmanK , ClerinxJ , KestensL . Human schistosomiasis. Lancet2006;368(9541):1106‐18. ">Gryseels 2006</a>; <a href="./references#CD000528-bbs2-0149" title="SteinmannP , KeiserJ , BosR , TannerM , UtzingerJ . Schistosomiasis and water resources development: systematic review, meta‐analysis, and estimates of people at risk. Lancet Infectious Diseases2006;6(7):411‐25. ">Steinmann 2006</a>; <a href="./references#CD000528-bbs2-0158" title="UtzingerJ , RasoG , BrookerS , deSavignyD , TannerM , OrnbjergN , et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology2009;136(13):1859‐74. ">Utzinger 2009</a>). It has been estimated that 779 million people are at risk of schistosomiasis worldwide and 207 million people may be infected (<a href="./references#CD000528-bbs2-0149" title="SteinmannP , KeiserJ , BosR , TannerM , UtzingerJ . Schistosomiasis and water resources development: systematic review, meta‐analysis, and estimates of people at risk. Lancet Infectious Diseases2006;6(7):411‐25. ">Steinmann 2006</a>). Of these, 120 million people are estimated to be symptomatic and 20 million suffer from long‐term complications (<a href="./references#CD000528-bbs2-0089" title="ChitsuloL , EngelsD , MontresorA , SavioliL . The global status of schistosomiasis and its control. Acta Tropica2000;77(1):41‐51. ">Chitsulo 2000</a>; <a href="./references#CD000528-bbs2-0163" title="WHO . Prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1‐57. 2002. ">WHO 2002</a>; <a href="./references#CD000528-bbs2-0159" title="van derWerfMJ , deVlasSJ , BrookerS , LoomanCW , NagelkerkeNJ , HabbemaJDF , et al. Quantification of clinical morbidity associated with schistosome infection in sub‐Saharan Africa. Acta Tropica2003;86(2‐3):125‐39. ">van der Werf 2003</a>). In global burden of disease estimates, schistosomiasis causes 1.7 to 4.5 million disability‐adjusted life years (DALYs) (<a href="./references#CD000528-bbs2-0163" title="WHO . Prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1‐57. 2002. ">WHO 2002</a>; <a href="./references#CD000528-bbs2-0164" title="WHO . World Health Report, World Health Organization, Geneva, Switzerland. 2004. ">WHO 2004</a>; <a href="./references#CD000528-bbs2-0123" title="HotezPJ , MolyneuxDH , FenwickA , OttesenE , Ehrlich SachsS , SachsJD . Incorporating a rapid‐impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Medicine2006;3:e102. ">Hotez 2006</a>; <a href="./references#CD000528-bbs2-0149" title="SteinmannP , KeiserJ , BosR , TannerM , UtzingerJ . Schistosomiasis and water resources development: systematic review, meta‐analysis, and estimates of people at risk. Lancet Infectious Diseases2006;6(7):411‐25. ">Steinmann 2006</a>; <a href="./references#CD000528-bbs2-0158" title="UtzingerJ , RasoG , BrookerS , deSavignyD , TannerM , OrnbjergN , et al. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology2009;136(13):1859‐74. ">Utzinger 2009</a>). Some suggest that this value may underestimate the true burden of schistosomiasis (<a href="./references#CD000528-bbs2-0163" title="WHO . Prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1‐57. 2002. ">WHO 2002</a>; <a href="./references#CD000528-bbs2-0159" title="van derWerfMJ , deVlasSJ , BrookerS , LoomanCW , NagelkerkeNJ , HabbemaJDF , et al. Quantification of clinical morbidity associated with schistosome infection in sub‐Saharan Africa. Acta Tropica2003;86(2‐3):125‐39. ">van der Werf 2003</a>; <a href="./references#CD000528-bbs2-0128" title="KingCH , DickmanK , TischDJ . Reassessment of the cost of chronic helminthic infection: a meta‐analysis of disability‐related outcomes in endemic schistosomiasis. Lancet2005;365(9470):1561‐9. ">King 2005</a>; <a href="./references#CD000528-bbs2-0129" title="KingCH . Lifting the burden of schistosomiasis‐‐defining elements of infection‐associated disease and the benefits of antiparasite treatment. Journal of Infectious Diseases2007;196(5):653‐5. ">King 2007</a>; <a href="./references#CD000528-bbs2-0130" title="KingCH , BertinoA‐M . Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. PLoS Neglected Tropical Diseases2008;2(3):1‐10. ">King 2008a</a>; <a href="./references#CD000528-bbs2-0132" title="KingCH . Health metrics for helminthic infections. Advances in Parasitology2010;73:51‐69. ">King 2010</a>). </p> <p>People infected with <i>S. mansoni</i> excrete the fluke eggs in their faeces, and faecal contamination of freshwater allows these eggs to hatch into larvae (miracidia) which penetrate a specific freshwater snail (the intermediate host). Within the snail, the miracidia develop into cercariae (the infective larvae), which can penetrate a person’s skin upon contact with contaminated water bodies. </p> <p>Following infection, the worms migrate through the human venous system, via the right chamber of the heart and the lungs, and through the mesenteric arteries and the liver via the portal vein, before finally settling in the superior mesenteric veins which drain the large intestine. Here, male and female worms mature, pair up and the female worms start to produce eggs (≂ 300 per day) (<a href="./references#CD000528-bbs2-0097" title="DavisA . Schistosomiasis [Section 11, Chapter 82: Helminth infections]. Manson's Tropical Diseases. 22nd Edition. WB Saunders, 2009:1425‐60. ">Davis 2009</a>). An adult worm usually lives for three to five years, but some can live up to 30 years (<a href="./references#CD000528-bbs2-0117" title="GryseelsB , PolmanK , ClerinxJ , KestensL . Human schistosomiasis. Lancet2006;368(9541):1106‐18. ">Gryseels 2006</a>). The eggs produced by the worms traverse the intestinal wall to be excreted in the faeces, and in the process some become trapped and initiate inflammatory reactions, which cause the underlying pathology and symptomatic illness (<a href="./references#CD000528-bbs2-0143" title="RichterJ . The impact of chemotherapy on morbidity due to schistosomiasis. Acta Tropica2003;86(2‐3):161‐83. ">Richter 2003a</a>; <a href="./references#CD000528-bbs2-0131" title="KingCH , Dangerfield‐ChaM . The unacknowledged impact of chronic schistosomiasis. Chronic Illness2008;4:65‐79. ">King 2008b</a>). Early symptoms depend on the severity of infection (<a href="./references#CD000528-bbs2-0066" title="GryseelsB , NkulikyinkaL , CoosemansMH . Field trials of praziquantel and oxamniquine for the treatment of schistosomiasis mansoni in Burundi. Transactions of the Royal Society of Tropical Medicine and Hygiene1987;81(4):641‐4. ">Gryseels 1987</a>), and if treatment is not provided early, chronic illness and long‐term serious disease can follow. </p> <section id="CD000528-sec-0033"> <h4 class="title">Symptoms and effects</h4> <p>Schistosomiasis mansoni can present as an acute or chronic illness. The acute illness, or Katayama syndrome, is caused by migrating and maturing schistosomula that may result in a systemic hypersensitivity reaction characterized by fever, feeling of general discomfort (malaise), muscle pain (myalgia), fatigue, non‐productive cough, diarrhoea (with or without blood), and pain in the upper right part of the abdomen just below the rib cage. Chronic and advanced disease results from the host's immune response to schistosome eggs deposited in tissues and the granulomatous reaction evoked by the antigens they secrete and is characterized by non‐specific intestinal symptoms, such as abdominal pain, diarrhoea and blood in the stool (<a href="./references#CD000528-bbs2-0115" title="GryseelsB , PoldermanAM , EngelsD . Experiences with the control of schistosomiasis mansoni in two foci in central Africa. Memorias do Instituto Oswaldo Cruz1992;87(Suppl 4):187‐94. ">Gryseels 1992</a>; <a href="./references#CD000528-bbs2-0114" title="GrayDJ , RossAG , LiY‐S , McManusDP . Diagnosis and management of schistosomiasis. BMJ2011;342:d2651. ">Gray 2011</a>; <a href="./references#CD000528-bbs2-0118" title="GryseelsB . Schistosomiasis. Infectious Disease Clinics of North America2012;26(2):383‐97. ">Gryseels 2012</a>). </p> <p>Inflammatory reactions in the liver lead to hepatosplenic schistosomiasis, a key feature of chronic infection, which can manifest within a couple of months for heavy infections or many years after light infections. The chronic inflammation produces fibrotic lesions, which in turn lead to liver cirrhosis that progressively occludes the portal system giving rise to portal hypertension. The portal hypertension eventually leads to enlargement of hepatic arteries, and the associated oesophageal varices may rupture with heavy blood loss, haemorrhagic shock and death. The patient may also suffer repeated episodes of variceal bleeding – the primary cause of death in hepatic schistosomiasis (<a href="./references#CD000528-bbs2-0082" title="AnderssonKL , ChungRT . Hepatic schistosomiasis: Current Treatment Options. Gastroenterology2007;10(6):504‐12. ">Andersson 2007</a>). Severity of disease depends upon the intensity and duration of infection (<a href="./references#CD000528-bbs2-0140" title="NausCW , BoothM , JonesFM , KemijumbiJ , VennervaldBJ , KariukiCH , et al. The relationship between age, sex, egg‐count and specific antibody responses against Schistosoma mansoni antigens in a Ugandan fishing community. Tropical Medicine and International Health2003;8(6):561‐8. ">Naus 2003</a>), but recent evidence suggests the presence of the infection alone determines morbidity (<a href="./references#CD000528-bbs2-0130" title="KingCH , BertinoA‐M . Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. PLoS Neglected Tropical Diseases2008;2(3):1‐10. ">King 2008a</a>). </p> <p><i>S. mansoni</i> infection overlaps in distribution with <i>S. haematobium</i> in some areas of sub‐Saharan Africa resulting in mixed infections (<a href="./references#CD000528-bbs2-0163" title="WHO . Prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1‐57. 2002. ">WHO 2002</a>). Unlike <i>S. mansoni</i> , the main early symptoms of <i>S. haematobium</i> infection are blood in urine (haematuria) and painful urination (dysuria). Chronic and advanced disease is insidious and may result in structural damage to the bladder wall which may eventually lead to kidney failure. </p> </section> <section id="CD000528-sec-0034"> <h4 class="title">Diagnosis</h4> <p>Definitive diagnosis of <i>S. mansoni</i> infection is by microscopy for parasite eggs in the stool. Quantitative methods are recommended for epidemiological purposes because they allow estimation of intensity and evaluation of the impact of control programmes not only in terms of cure rate but also egg reduction rate (<a href="./references#CD000528-bbs2-0161" title="WHO . The control of schistosomiasis. Report of WHO expert committee. WHO Technical Report Series No. 728. Geneva. 1985. ">WHO 1985</a>; <a href="./references#CD000528-bbs2-0103" title="DoenhoffMJ , ChiodiniPL , HamiltonJV . Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies?. Trends in Parasitology2004;20(1):35‐9. ">Doenhoff 2004</a>; <a href="./references#CD000528-bbs2-0083" title="BergquistR , JohansenMV , UtzingerJ . Diagnostic dilemmas in helminthology: what tools to use and when?. Trends in Parasitology2009;25(4):151‐6. ">Bergquist 2009</a>). The Kato‐Katz technique (<a href="./references#CD000528-bbs2-0126" title="KatzN , ChavesA , PellegrinoJ . A simple device for quantitative stool thick‐smear technique in Schistosomiasis mansoni . Revista do Instituto de Medicina Tropical de São Paulo1972;14(6):397‐400. ">Katz 1972</a>) is the most common quantitative technique (<a href="./references#CD000528-bbs2-0084" title="BoothM , VounatsouP , N'GoranEK , TannerM , UtzingerJ . The influence of sampling effort and the performance of the Kato‐Katz technique in diagnosing Schistosoma mansoni and hookworm co‐infections in rural Côte d'Ivoire. Parasitology2003;127(Pt 6):525‐31. ">Booth 2003</a>). Recently, the FLOTAC technique has been applied for the detection and quantification of <i>S. mansoni</i> eggs in stools with promising results and hence warranting further investigation (<a href="./references#CD000528-bbs2-0113" title="GlinzD , KigbaforiSD , KnoppS , YaoPK , LohourignonLK , SteinmannP , et al. Comparison of Kato‐Katz, koga agar plate, ether‐concentration, and FLOTAC techniques for the diagnosis of Schistosoma mansoni and soil‐transmitted helminths. PLoS Neglected Tropical Diseases2010;4(7):e754. ">Glinz 2010</a>). </p> <p>Egg output can be influenced by several factors, such as day‐to‐day, intra‐stool, and seasonal variations as well as environmental conditions (<a href="./references#CD000528-bbs2-0087" title="Braun‐MunzingerRA , SouthgateBA . Repeatability and reproducibility of egg counts of Schistosoma haematobium in urine. Tropical Medicine and Parasitology1992;43(3):149‐54. ">Braun‐Munzinger 1992</a>; <a href="./references#CD000528-bbs2-0105" title="EngelsD , SinzinkayoE , GryseelsB . Day‐to‐day egg count fluctuation in Schistosoma mansoni infection and its operational implications. American Journal of Tropical Medicine and Hygiene1996;54(4):319‐24. ">Engels 1996</a>; <a href="./references#CD000528-bbs2-0106" title="EngelsD , SinzinkayoE , DeVlasSJ , GryseelsB . Intraspecimen fecal egg count variation in Schistosoma mansoni infection. American Journal of Tropical Medicine and Hygiene1997;57(5):571‐7. ">Engels 1997</a>; <a href="./references#CD000528-bbs2-0108" title="EnkMJ , LimaAC , DrummondSC , SchallVT , CoelhoPM . The effect of the number of stool samples on the observed prevalence and the infection intensity with Schistosoma mansoni among a population in an area of low transmission. Acta Tropica2008;108(2‐3):222‐8. ">Enk 2008</a>). Therefore negative results following microscopic examination of a single stool are unreliable (<a href="./references#CD000528-bbs2-0099" title="deVlasSJ , GryseelsB . Underestimation of Schistosoma mansoni prevalences. Parasitology Today1992;8:274‐7. ">de Vlas 1992</a>; <a href="./references#CD000528-bbs2-0133" title="KongsA , MarksG , VerléP , Van derStuyftP . The unreliability of the Kato‐Katz technique limits its usefulness for evaluating S. mansoni infections. Tropical Medicine and International Health2001;6(3):163‐9. ">Kongs 2001</a>; <a href="./references#CD000528-bbs2-0084" title="BoothM , VounatsouP , N'GoranEK , TannerM , UtzingerJ . The influence of sampling effort and the performance of the Kato‐Katz technique in diagnosing Schistosoma mansoni and hookworm co‐infections in rural Côte d'Ivoire. Parasitology2003;127(Pt 6):525‐31. ">Booth 2003</a>; <a href="./references#CD000528-bbs2-0108" title="EnkMJ , LimaAC , DrummondSC , SchallVT , CoelhoPM . The effect of the number of stool samples on the observed prevalence and the infection intensity with Schistosoma mansoni among a population in an area of low transmission. Acta Tropica2008;108(2‐3):222‐8. ">Enk 2008</a>), and measurement of prevalence and intensity of infection by egg count has shortcomings (<a href="./references#CD000528-bbs2-0116" title="GryseelsB , deVlasSJ . Worm burdens in schistosome infections. Parasitology Today1996;12(3):115‐9. ">Gryseels 1996</a>; <a href="./references#CD000528-bbs2-0100" title="deVlasSJ , EngelsD , RabelloAL , OostburgBF , VanLieshoutL , PoldermanAM , et al. Validation of a chart to estimate true Schistosoma mansoni prevalences from simple egg counts. Parasitology1997;114(Pt 2):113‐21. ">de Vlas 1997</a>; <a href="./references#CD000528-bbs2-0154" title="UtzingerJ , BoothM , NGoranEK , MüllerI , TannerM , LengelerC . Relative contribution of day‐to‐day and intra‐specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel. Parasitology2001;122(Pt 5):537‐44. ">Utzinger 2001a</a>). Rectal biopsy is more sensitive than microscopy and is occasionally done when repeated stool examinations are negative for eggs. However, this method is unsuitable for use in population‐based control programmes (<a href="./references#CD000528-bbs2-0081" title="AllanRW . The Johns Hopkins Hospital, Department of Pathology. Johns Hopkins Microbiology Newsletter 2001;20:30. ">Allan 2001</a>). </p> <p>A monoclonal antibody‐based dipstick is increasingly being used for the diagnosis of the infection with promising results (<a href="./references#CD000528-bbs2-0141" title="PolmanK , StelmaFF , deVlasSJ , SowS , FathersL , LeCessieS , et al. Dynamics of egg counts and circulating antigen levels in a recent Schistosoma mansoni focus in northern Senegal. Tropical Medicine and International Health2001;6:538‐44. ">Polman 2001</a>; <a href="./references#CD000528-bbs2-0135" title="LegesseM , ErkoB . Field‐based evaluation of a reagent strip test for diagnosis of Schistosoma mansoni by detecting circulating cathodic antigen in urine before and after chemotherapy. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(7):668‐73. ">Legesse 2007</a>; <a href="./references#CD000528-bbs2-0136" title="LegesseM , ErkoB . Field‐based evaluation of a reagent strip test for diagnosis of schistosomiasis mansoni by detecting circulating cathodic antigen (CCA) in urine in low endemic area in Ethiopia. Parasite2008;15(2):151‐5. ">Legesse 2008</a>; <a href="./references#CD000528-bbs2-0088" title="CoulibalyJT , KnoppS , N'GuessanNA , SiluéKD , FürstT , LohourignonLK , et al. Accuracy of urine circulating cathodic antigen (CCA) test for Schistosoma mansoni diagnosis in different settings of Côte d'Ivoire. PLoS Neglected Tropical Diseases2011;5(11):e1384. ">Caulibaly 2011</a>). A more specific and sensitive diagnostic technique based on polymerase chain reaction (PCR) is increasingly being used in some reference laboratories in Europe (<a href="./references#CD000528-bbs2-0146" title="SandovalN , Siles‐LucasM , Pérez‐ArellanoJL , CarranzaC , PuenteS , López‐AbánJ , et al. A new PCR‐based approach for the specific amplification of DNA from different Schistosoma species applicable to human urine samples. Parasitology2006;133(Pt 5):581‐7. ">Sandoval 2006</a>; <a href="./references#CD000528-bbs2-0091" title="CnopsL , TannichE , PolmanK , ClerinxJ , VanEsbroeckM . Schistosoma real‐time PCR as diagnostic tool for international travellers and migrants. Tropical Medical International Health2012;17(10):1208‐16. ">Cnops 2012</a>; <a href="./references#CD000528-bbs2-0109" title="EnkMJ , Oliveirae Silva G , RodriguesNB . Diagnostic accuracy and applicability of a PCR system for the detection of Schistosoma mansoni DNA in human urine samples from an endemic area. PLoS One2012;7(6):e38947. ">Enk 2012</a>). Ultrasound is used for diagnosing and assessing infection‐related pathology (<a href="./references#CD000528-bbs2-0120" title="HatzCF , SavioliL , MayombanaC , DhunputhJ , KisumkuUM , TannerM . Measurement of schistosomiasis‐related morbidity at community level in areas of different endemicity. Bulletin of the World Health Organization1990;68(6):777‐87. ">Hatz 1990</a>; <a href="./references#CD000528-bbs2-0139" title="Mohamed‐AliQ , Doehring‐SchwerdtfegerE , Abdel‐RahimIM , SchlakeJ , KardorffR , FrankeD , et al. Ultrasonographical investigations of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity seven months after treatment with praziquantel. American Journal of Tropical Medicine and Hygiene1991;44:444‐51. ">Mohamed‐Ali 1991</a>; <a href="./references#CD000528-bbs2-0101" title="Doehring‐SchwerdtfegerE , Abdel‐RahimIM , KardorffR , KaiserC , FrankeD , SchlakeJ , et al. Ultrasonographical investigations of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty‐three months after treatment with praziquantel. American Journal of Tropical Medicine and Hygiene1992;46:409‐15. ">Doehring‐Schwerdtfeger 1992</a>; <a href="./references#CD000528-bbs2-0121" title="HatzCF . The use of ultrasound in schistosomiasis. Advances in Parasitology2001;48:225‐84. ">Hatz 2001</a>; <a href="./references#CD000528-bbs2-0144" title="RichterJ , HatzC , HäussingerD . Ultrasound in tropical and parasitic diseases. Lancet2003;362(9387):900‐2. ">Richter 2003b</a>). </p> <p>Clinically, intestinal schistosomiasis is diagnosed on the basis of presence of blood in stool, (bloody) diarrhoea, and abdominal pain, but these are non‐sensitive and non‐specific (<a href="./references#CD000528-bbs2-0115" title="GryseelsB , PoldermanAM , EngelsD . Experiences with the control of schistosomiasis mansoni in two foci in central Africa. Memorias do Instituto Oswaldo Cruz1992;87(Suppl 4):187‐94. ">Gryseels 1992</a>; <a href="./references#CD000528-bbs2-0152" title="UtzingerJ , N'GoranEK , OsseyYA , BoothM , TraoréM , LohourignonKL , et al. Rapid screening for Schistosoma mansoni in western Côte d'Ivoire using a simple school questionnaire. Bulletin of the World Health Organization2000;78(3):389‐98. ">Utzinger 2000c</a>; <a href="./references#CD000528-bbs2-0094" title="Danso‐AppiahA , deVlasSJ , BosompemKM , HabbemaJDF . Determinants of health‐seeking behaviour for schistosomiasis‐related symptoms in the context of integrating schistosomiasis control within the regular health services in Ghana. Tropical Medicine and International Health2004;9(7):784–94. ">Danso‐Appiah 2004</a>) as diarrhoea or blood in stool can be due to other causes such as hookworm infection, dysentery and typhoid fever. </p> </section> </section> <section id="CD000528-sec-0035"> <h3 class="title" id="CD000528-sec-0035">Description of the intervention</h3> <p>Schistosomiasis control measures implemented before the 1970s – when efficacious antischistosomal drugs were not available – focused mainly on interrupting transmission with molluscicides to kill the intermediate host snails (<a href="./references#CD000528-bbs2-0161" title="WHO . The control of schistosomiasis. Report of WHO expert committee. WHO Technical Report Series No. 728. Geneva. 1985. ">WHO 1985</a>; <a href="./references#CD000528-bbs2-0150" title="SturrockRF . Schistosomiasis epidemiology and control: how did we get here and where should we go?. Memorias do Instituto Oswaldo Cruz2001;96(Suppl):17‐27. ">Sturrock 2001</a>). The 1970s marked the turning point in schistosomiasis control when efficacious drugs that can be applied in a single oral dose were discovered, shifting the control emphasis from transmission control to chemotherapy‐based morbidity control (<a href="./references#CD000528-bbs2-0161" title="WHO . The control of schistosomiasis. Report of WHO expert committee. WHO Technical Report Series No. 728. Geneva. 1985. ">WHO 1985</a>; <a href="./references#CD000528-bbs2-0090" title="CioliD , Pica‐MattocciaL , ArcherS . Antischistosomal drugs: past, present ... and future?. Pharmacology and Therapeutics1995;68(1):35‐85. ">Cioli 1995</a>). A body of evidence suggests that morbidity due to schistosomiasis can be prevented and pathology reversed with available antischistosomal treatments (<a href="./references#CD000528-bbs2-0139" title="Mohamed‐AliQ , Doehring‐SchwerdtfegerE , Abdel‐RahimIM , SchlakeJ , KardorffR , FrankeD , et al. Ultrasonographical investigations of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity seven months after treatment with praziquantel. American Journal of Tropical Medicine and Hygiene1991;44:444‐51. ">Mohamed‐Ali 1991</a>; <a href="./references#CD000528-bbs2-0101" title="Doehring‐SchwerdtfegerE , Abdel‐RahimIM , KardorffR , KaiserC , FrankeD , SchlakeJ , et al. Ultrasonographical investigations of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty‐three months after treatment with praziquantel. American Journal of Tropical Medicine and Hygiene1992;46:409‐15. ">Doehring‐Schwerdtfeger 1992</a>; <a href="./references#CD000528-bbs2-0147" title="SavioliL , AlbonicoM , EngelsD , MontresorA . Progress in the prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Parasitology International2004;53(2):103‐13. ">Savioli 2004</a>; <a href="./references#CD000528-bbs2-0166" title="ZhangY , KoukounariA , KabatereineN , FlemingF , KazibweF , TukahebwaE , et al. Parasitological impact of 2‐year preventive chemotherapy on schistosomiasis and soil‐transmitted helminthiasis in Uganda. BMC Medicine2007;3:5:27. ">Zhang 2007</a>; <a href="./references#CD000528-bbs2-0160" title="WebsterJP , KoukounariA , LambertonPH , StothardJR , FenwickA . Evaluation and application of potential schistosome‐associated morbidity markers within large‐scale mass chemotherapy programmes. Parasitology2009;136(13):1789‐99. ">Webster 2009</a>; <a href="./references#CD000528-bbs2-0134" title="KoukounariA , DonnellyCA , SackoM , KeitaAD , LandoureA , DembeleR , et al. The impact of single versus mixed schistosome species infections on liver, spleen and bladder morbidity within Malian children pre‐ and post‐praziquantel treatment. BMC Infectious Diseases2010;10(1):227. ">Koukounari 2010</a>). </p> <p>Mass drug administration, or treatment of infected individuals or entire 'at‐risk' populations (eg school‐aged children), usually without prior diagnosis ‐ an approach termed 'preventive chemotherapy', is the control strategy currently pursued by the World Health Organization (WHO) and applied in many endemic countries (<a href="./references#CD000528-bbs2-0165" title="WHO . Preventive Chemotherapy guidelines. Report of a WHO expert committee, World Health Organization, Geneva, Switzerland. 2006. ">WHO 2006</a>). Usually, praziquantel at a single 40 mg/kg oral dose is used (<a href="./references#CD000528-bbs2-0111" title="FenwickA , WebsterJP , Bosque‐OlivaE , BlairL , FlemingFM , ZhangY , et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002‐2008. Parasitology2009;136(13):1719‐30. ">Fenwick 2009</a>), but still there are uncertainties regarding this dose. An exception is Brazil where the national policy adopted since 1995 recommends a single oral dose of 60 mg/kg for children aged between two and 15 years, and 50 mg/kg for adolescents and adults (<a href="./references#CD000528-bbs2-0110" title="FavreTC , PereiraAP , GalvãoAF , ZaniLC , BarbosaCS , PieriOS . A rationale for schistosomiasis control in elementary schools of the rainforest zone of Pernambuco, Brazil. PLoS Neglected Tropical Diseases2009;3(3):e395.doi:10.1371/journal.pntd.0000395. ">Favre 2009</a>). The recently adopted policy for schistosomiasis control in Brazil disapproves of treatment without prior diagnosis, and therefore the preventive chemotherapy strategy is no longer applied in Brazil (<a href="./references#CD000528-bbs2-0110" title="FavreTC , PereiraAP , GalvãoAF , ZaniLC , BarbosaCS , PieriOS . A rationale for schistosomiasis control in elementary schools of the rainforest zone of Pernambuco, Brazil. PLoS Neglected Tropical Diseases2009;3(3):e395.doi:10.1371/journal.pntd.0000395. ">Favre 2009</a>). </p> <p>Oxamniquine has also been used extensively for the control of schistosomiasis mansoni in different endemic countries, most notably Brazil, where more than 12 million doses of oxamniquine have been administered by the national schistosomiasis control programme (<a href="./references#CD000528-bbs2-0127" title="KatzN , CoelhoPM . Clinical therapy of schistosomiasis mansoni: the Brazilian contribution. Acta Tropica2008;108(2‐3):72‐8. ">Katz 2008</a>). There are uncertainties around the standard dose of oxamniquine (<a href="./references#CD000528-bbs2-0112" title="FosterR . A review of clinical experience with oxamniquine. Transactions of the Royal Society of Tropical Medicine and Hygiene1987;81(1):55‐9. ">Foster 1987</a>; <a href="./references#CD000528-bbs2-0090" title="CioliD , Pica‐MattocciaL , ArcherS . Antischistosomal drugs: past, present ... and future?. Pharmacology and Therapeutics1995;68(1):35‐85. ">Cioli 1995</a>). Therefore, the WHO recommends total doses of 20 to 60 mg/kg (in divided doses of up to 20 mg/kg) (<a href="./references#CD000528-bbs2-0162" title="WHO Expert Committee on the Control of Schistosomiasis (Geneva, Switzerland) . Prevention and Control of Schistosomiasis and soil‐transmitted helminthiasis: report of a WHO expert committee. WHO Technical Report Series 912. 2001. ">WHO 2001</a>). </p> <p>More recently, the artemisinin derivatives used in the treatment of malaria have been shown to have antischistosomal properties, particularly against the immature developing stages of the schistosome parasites (<a href="./references#CD000528-bbs2-0085" title="BorrmannS , SzlezákN , FaucherJF , MatsieguiPB , NeubauerR , BinderRK , et al. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double‐blind, randomized, placebo‐controlled study. Journal of Infectious Diseases2001;184(10):1363‐6. ">Borrmann 2001</a>; <a href="./references#CD000528-bbs2-0157" title="UtzingerJ , XiaoSH , TannerM , KeiserJ . Artemisinins for schistosomiasis and beyond. Current Opinion on Investigational Drugs2007;8(2):105‐16. ">Utzinger 2007</a>). Praziquantel, in contrast, acts against the adult worms and the very young schistosomula just after skin penetration (<a href="./references#CD000528-bbs2-0145" title="SabahAA , FletcherC , WebbeG , DoenhoffMJ . Schistosoma mansoni: chemotherapy of infections of different ages. Experimental Parasitology1986;61:294‐303. ">Sabah 1986</a>; <a href="./references#CD000528-bbs2-0157" title="UtzingerJ , XiaoSH , TannerM , KeiserJ . Artemisinins for schistosomiasis and beyond. Current Opinion on Investigational Drugs2007;8(2):105‐16. ">Utzinger 2007</a>). </p> <p>The current emphasis of schistosomiasis control is to reduce the burden of disease in high endemicity areas and to interrupt transmission in low endemicity areas (<a href="./references#CD000528-bbs2-0163" title="WHO . Prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1‐57. 2002. ">WHO 2002</a>). Intensity of infection is highest in school‐aged children and adolescents, therefore preventive chemotherapy is targeted especially to these at‐risk groups (<a href="./references#CD000528-bbs2-0138" title="MagnussenP , NdawiB , ShesheAK , ByskovJ , MbwanaK , ChristensenNO . The impact of a school health programme on the prevalence and morbidity of urinary schistosomiasis in Mwera Division, Pangani District, Tanzania. Transactions of the Royal Society of Tropical Medicine and Hygiene2001;95(1):58‐64. ">Magnussen 2001</a>; <a href="./references#CD000528-bbs2-0163" title="WHO . Prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1‐57. 2002. ">WHO 2002</a>; <a href="./references#CD000528-bbs2-0147" title="SavioliL , AlbonicoM , EngelsD , MontresorA . Progress in the prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Parasitology International2004;53(2):103‐13. ">Savioli 2004</a>; <a href="./references#CD000528-bbs2-0148" title="SavioliL , GabrielliAF , MontresorA , ChitsuloL , EngelsD . Schistosomiasis control in Africa: 8 years after World Health Assembly Resolution 54.19. Parasitology2009;136(13):1677‐81. ">Savioli 2009</a>). </p> <p>The efficacy of myrrh (Mirazid) in the treatment of intestinal schistosomiasis has been evaluated in Egypt (<a href="./references#CD000528-bbs2-0005" title="BarakatR , ElmorshedyH , FenwickA . Efficacy of myrrh in the treatment of human schistosomiasis mansoni. American Journal of Tropical Medicine and Hygiene2005;73(2):365‐7. ">Barakat 2005 EGY</a>; <a href="./references#CD000528-bbs2-0006" title="BotrosS , SayedH , El‐DusokiH , SabryH , RabieI , El‐GhannamM , et al. Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni‐infected school children and households. American Journal of Tropical Medicine and Hygiene2005;72(2):119‐23. ">Botros 2005 EGY</a>). </p> </section> <section id="CD000528-sec-0036"> <h3 class="title" id="CD000528-sec-0036">Why it is important to do this review</h3> <p>Currently, entire control and treatment programmes are based on praziquantel and there is risk of drug resistance and perhaps shortages of praziquantel. There is a need to assess alternative drugs or combinations. Still there are uncertainties around effective and safe dosage of praziquantel and standard doses of oxamniquine. There are also uncertainties about adequacy of current adult doses used in children. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000528-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000528-sec-0037"></div> <p>To evaluate the effects of antischistosomal drugs, used alone or in combination, for treating <i>S. mansoni</i> infection. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000528-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000528-sec-0038"></div> <section id="CD000528-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000528-sec-0040"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials.</p> </section> <section id="CD000528-sec-0041"> <h4 class="title">Types of participants</h4> <p>Individuals infected with <i>S. mansoni</i> diagnosed microscopically for the presence of <i>S. mansoni</i> eggs in stool using the Kato‐Katz technique (<a href="./references#CD000528-bbs2-0126" title="KatzN , ChavesA , PellegrinoJ . A simple device for quantitative stool thick‐smear technique in Schistosomiasis mansoni . Revista do Instituto de Medicina Tropical de São Paulo1972;14(6):397‐400. ">Katz 1972</a>), or any other quantitative diagnostic method, such as the quantitative oogram and FLOTAC techniques. </p> </section> <section id="CD000528-sec-0042"> <h4 class="title">Types of interventions</h4> <p>The following comparisons are evaluated in this review:</p> <p> <ol id="CD000528-list-0001"> <li> <p>Antischistosomal drugs alone or in combination versus placebo;</p> </li> <li> <p>Antischistosomal drugs alone or in combination versus a different dose of the same antischistosomal drug; and </p> </li> <li> <p>Antischistosomal drugs alone or in combination versus different antischistosomal drugs alone or in combination. </p> </li> </ol> </p> <p>Trials that allocated non‐schistosomal drug or interventions in addition to the treatment and control of interest were eligible provided the same drug was allocated to both treatment and control groups. </p> </section> <section id="CD000528-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD000528-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD000528-list-0002"> <li> <p>Parasitological failure, defined as treated individuals who remained positive for <i>S. mansoni</i> eggs in stool using the standard Kato‐Katz or other quantitative techniques (follow‐up: up to one month). </p> </li> <li> <p>Egg reduction rate, defined as percent reduction in <i>S. mansoni</i> egg count after treatment (follow‐up: up to 12 months). </p> </li> </ul> </p> </section> <section id="CD000528-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD000528-list-0003"> <li> <p>Parasitological failure (follow‐up: greater than one month).</p> </li> <li> <p>Resolution of symptoms (eg abdominal pain, diarrhoea and bloody diarrhoea).</p> </li> <li> <p>Resolution of pathology (eg hepatomegaly, splenomegaly, portal fibrosis, cirrhosis of the liver or colonic polyps) measured by ultrasound, by standard international classification or other standardized methods (<a href="./references#CD000528-bbs2-0092" title="Cairo Working Group (CWG). The use of diagnostic ultrasound in schistosomiasis‐‐attempts at standardization of methodology. Acta Tropica1992;51(1):45‐63. ">CWG 1992</a>). </p> </li> </ul> </p> <section id="CD000528-sec-0046"> <h6 class="title">Adverse events</h6> <p> <ul id="CD000528-list-0004"> <li> <p>Non‐serious adverse events.</p> </li> <li> <p>Serious adverse events (ie any untoward medical occurrence or effect that at any dose: results in death; is life‐threatening; requires hospitalisation or prolongation of existing inpatients' hospitalisation; results in persistent or significant disability or incapacity; is a congenital anomaly or birth defect). </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD000528-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, under review and in progress). </p> <section id="CD000528-sec-0048"> <h4 class="title">Electronic searches</h4> <section id="CD000528-sec-0049"> <h5 class="title">Databases</h5> <p>We searched the following databases using the search terms and strategy described in <a href="#CD000528-tbl-0005">Table 1</a>: Cochrane Infectious Diseases Group Specialized Register (October 2012); Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE (1966 to October 2012); EMBASE (1974 to October 2012); and LILACS (1982 to October 2012). We also searched the <i>meta</i> Register of Controlled Trials (mRCT) in October 2012 using <i>’Schisto</i> * <i>mansoni'</i> as the search term. </p> <div class="table" id="CD000528-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed search strategies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Search set</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIDG SR^</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CENTRAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MEDLINE^^</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EMBASE^^</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LILACS^^</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schisto* mansoni</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>SCHISTOSOMA MANSONI</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>SCHISTOSOMA MANSONI</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>SCHISTOSOMA MANSONI</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schisto$ mansoni</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCHISTOSOMIASIS MANSONI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCHISTOSOMIASIS MANSONI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCHISTOSOMIASIS MANSONI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intestinal schistosom* ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intestinal schistosom* ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intestinal schistosom$ ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bilharzia*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bilharzia*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bilharzia$</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schistosomicide*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schistosomicide*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schistosomicide$</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 or 3 or 4 or 5 or 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 or 3 or 4 or 5 or 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 or 3 or 4 or 5 or 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limit 7 to humans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limit 7 to humans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>^Cochrane Infectious Diseases Group Specialized Register</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>^^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<a href="./references#CD000528-bbs2-0122" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>); Upper case: MeSH or EMTREE heading; Lower case: free text term </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0050"> <h4 class="title">Searching other resources</h4> <section id="CD000528-sec-0051"> <h5 class="title">Researchers and organizations</h5> <p>We contacted individual researchers working on antischistosomal drugs, pharmaceutical industries and experts from the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) for unpublished data and ongoing trials. </p> </section> <section id="CD000528-sec-0052"> <h5 class="title">Reference lists</h5> <p>We checked the reference lists of all studies identified by the aforementioned methods for additional relevant studies. </p> </section> </section> </section> <section id="CD000528-sec-0053"> <h3 class="title" id="CD000528-sec-0053">Data collection and analysis</h3> <section id="CD000528-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG) Information Retrieval Specialist, searched the literature and retrieved studies using the search strategy outlined in <a href="#CD000528-tbl-0005">Table 1</a>. Anthony Danso‐Appiah (ADA) screened the results to identify potentially relevant trials, obtained the full trial reports and assessed the eligibility of trials for inclusion in the review using an eligibility form based on the inclusion criteria. Jürg Utzinger (JU) independently verified the eligibility assessment results. </p> <p>ADA contacted the authors of potentially relevant trials for clarification if eligibility was unclear. We excluded studies that did not meet our inclusion criteria and we have detailed the reasons for exclusion in the <a href="./references#CD000528-sec-0160" title="">Characteristics of excluded studies</a>. This was verified independently by JU and Piero L. Olliaro (PLO). We resolved any discrepancies through discussion between the authors. </p> </section> <section id="CD000528-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>ADA extracted trial characteristics such as methods, participants, interventions and outcomes, and recorded on standard forms, which were independently verified by JU. ADA and JU resolved discrepancies through discussion, and where necessary contacted a third author (PLO). ADA contacted trial authors for clarification, or insufficient or missing data when necessary. </p> <p>We extracted the number of participants randomized and the number of patients followed‐up in each treatment arm. For dichotomous outcomes, we recorded the number of participants experiencing the event in each treatment group of the trial. For continuous outcomes summarized as geometric means, we extracted means and their standard deviations (SD) on the log scale. If the data were summarized as arithmetic mean, we extracted the means and their SDs. We extracted medians or ranges when they were reported to summarize the data. </p> <p>For each outcome, we extracted data for each follow‐up time reported in the trial report. </p> </section> <section id="CD000528-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>ADA assessed the risk of bias of each trial using The Cochrane Collaboration's risk of bias tool (<a href="./references#CD000528-bbs2-0122" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>) and the assessment results were verified independently by Dave Sinclair (DS). Where information in the trial report was unclear, we attempted to contact the trial authors for clarification. We assessed the risk of bias for six domains: sequence generation, allocation concealment, blinding (investigators, outcome assessors and participants), incomplete outcome data, selective outcome reporting and other sources of bias. For each domain, we made a judgment of 'low risk' of bias, 'high risk' of bias or 'unclear'. We resolved any discrepancies by discussion between the authors. </p> </section> <section id="CD000528-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <p>We presented dichotomous outcomes using risk ratios (RR). Mean differences (MD) were used as the measure of effect for continuous outcomes that were summarized as arithmetic means. We used geometric mean ratios for continuous outcomes that were summarized as geometric means. We presented all results with 95% confidence intervals (CI). </p> </section> <section id="CD000528-sec-0058"> <h4 class="title">Dealing with missing data</h4> <p>We analysed data based on the number of patients for whom an outcome was recorded (complete case analysis). </p> </section> <section id="CD000528-sec-0059"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by inspecting the forest plots for overlapping CIs and outlying data; using the Chi<sup>2</sup> test with a P value &lt; 0.1 to indicate statistically significant heterogeneity; and using the I<sup>2</sup> statistic. </p> </section> <section id="CD000528-sec-0060"> <h4 class="title">Assessment of reporting biases</h4> <p>We would have attempted to explore publication bias using funnel plots if there were sufficient number of trials in the comparisons. </p> </section> <section id="CD000528-sec-0061"> <h4 class="title">Data synthesis</h4> <p>We used <a href="./references#CD000528-bbs2-0142" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">Review Manager (RevMan)</a> to perform the statistical analyses. We stratified the analyses by: comparison; the dose of the drug; and the length of follow‐up time. We used meta‐analysis to combine the results across trials. When heterogeneity was detected, we used a random‐effects meta‐analysis approach; otherwise a fixed‐effect approach was adopted. We tabulated adverse events and also data that could not be meta‐analysed. </p> </section> <section id="CD000528-sec-0062"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>When heterogeneity was detected, we planned to carry out subgroup analyses to explore potential causes. Subgroupings would be as follows: patient age (children versus adults); and intensity of infection (&lt; 500 eggs per gram of stool versus &gt; 500 eggs per gram of stool). </p> <p>We conducted a subsidiary, non‐randomized comparison of failure rates in children with failure rates in adults for the same drug and same dose (mg/kg) to explore issues around dose applicability in children. </p> </section> <section id="CD000528-sec-0063"> <h4 class="title">Sensitivity analysis</h4> <p>Where data were sufficient we planned to conduct sensitivity analyses to assess the robustness of the results to the risk of bias components. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000528-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000528-sec-0064"></div> <section id="CD000528-sec-0065"> <h3 class="title">Description of studies</h3> <p>We identified 52 trials (10,269 participants) which met the inclusion criteria (see <a href="./references#CD000528-sec-0159" title="">Characteristics of included studies</a>). We managed one multicentre trial carried out in Brazil, Mauritania and Tanzania as three separate trials in the analysis (<a href="./references#CD000528-bbs2-0037" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 BRA</a>; <a href="./references#CD000528-bbs2-0038" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 MRT</a>; <a href="./references#CD000528-bbs2-0039" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 TZA</a>), and three papers contained multiple individual studies which we again managed separately (<a href="./references#CD000528-bbs2-0012" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976a ZWE</a>; <a href="./references#CD000528-bbs2-0013" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976b ZWE</a>; <a href="./references#CD000528-bbs2-0014" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976c ZWE</a>; <a href="./references#CD000528-bbs2-0015" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976d ZWE</a>; <a href="./references#CD000528-bbs2-0030" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979a BRA</a>; <a href="./references#CD000528-bbs2-0031" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979b BRA</a>; <a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a>; <a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a>; <a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a>). </p> <p>Of the 52 trials we identified, 19 evaluated praziquantel, 17 evaluated oxamniquine and 12 directly compared praziquantel with oxamniquine. In addition, two compared myrrh (mirazid) with praziquantel, and two compared different brands of praziquantel. </p> <p>Three trials assessed combination therapies: including praziquantel plus oxamniquine (<a href="./references#CD000528-bbs2-0008" title="CreaseyAM , TaylorP , ThomasJE . Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean schoolchildren. Central African Journal of Medicine1986;32(7):165‐7. ">Creasey 1986 ZWE</a>; <a href="./references#CD000528-bbs2-0052" title="ZwingenbergerK , QueirozJA , PoggenseeU , AlencarJE , ValdegunasJ , EsmeraldaF , et al. Efficacy of oxamniquine, praziquantel and a combination of both drugs in schistosomiasis mansoni in Brazil. Revista do Instituto de Medicina Tropical de São Paulo1987;29(5):305‐11. ">Zwingenberger 1987 BRA</a>) and praziquantel plus artesunate (<a href="./references#CD000528-bbs2-0016" title="DeClercqD , VercruysseJ , VerleP , KongsA , DiopM . What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections?. Tropical Medicine and International Health2000;5(10):744‐6. ">De Clercq 2000 SEN</a>). </p> <p>For the two primary outcomes, 47 trials reported cure rate or failure rate, 34 trials reported egg reduction rate and 33 trials reported both outcomes. Only <a href="./references#CD000528-bbs2-0047" title="SukwaTY . A community‐based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. Annals of Tropical Medicine and Parasitology1993;87(2):185‐94. ">Sukwa 1993 ZMB</a> reported reinfection rate. </p> <p>For secondary outcomes, five trials (<a href="./references#CD000528-bbs2-0044" title="RugemalilaJB , AsilaJ , ChimbeA . Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. Journal of Tropical Medicine and Hygiene1984;87(6):231‐5. ">Rugemalila 1984 TZA</a>; <a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a>; <a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a>; <a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a>; <a href="./references#CD000528-bbs2-0047" title="SukwaTY . A community‐based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. Annals of Tropical Medicine and Parasitology1993;87(2):185‐94. ">Sukwa 1993 ZMB</a>) reported clinical improvement or functional indices, but we could not include <a href="./references#CD000528-bbs2-0044" title="RugemalilaJB , AsilaJ , ChimbeA . Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. Journal of Tropical Medicine and Hygiene1984;87(6):231‐5. ">Rugemalila 1984 TZA</a> and <a href="./references#CD000528-bbs2-0047" title="SukwaTY . A community‐based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. Annals of Tropical Medicine and Parasitology1993;87(2):185‐94. ">Sukwa 1993 ZMB</a> in the meta‐analysis because of insufficient information. Thirty‐three trials reported adverse events. </p> <p>In the study by <a href="./references#CD000528-bbs2-0017" title="DoehringE , EhrichJH , VesterU , FeldmeierH , PoggenseeU , BrodehlJ . Proteinuria, hematuria, and leukocyturia in children with mixed urinary and intestinal schistosomiasis. Kidney International1985;28(3):520‐5. DoehringE , PoggenseeU , FeldmeierH . The effect of metrifonate in mixed Schistosoma haematobium and Schistosoma mansoni infections in humans. American Journal of Tropical Medicine and Hygiene1986;35(2):323‐9. FeldmeierH , GastlGA , PoggenseeU , KortmannC , DaffallaAA , PeterHH . Relationship between intensity of infection and immunomodulation in human schistosomiasis. II. NK cell activity and in vitro lymphocyte proliferation. Clinical and Experimental Immunology1985;60(2):234‐40. FeldmeierH , Nogueira‐QueirozJA , Peixoto‐QueirozMA , DoehringE , DessaintJP , deAlencarJE , et al. Detection and quantification of circulating antigen in schistosomiasis by monoclonal antibody. II. The quantification of circulating antigens in human schistosomiasis mansoni and haematobium: relationship to intensity of infection and disease status. Clinical and Experimental Immunology1986;65(2):232‐43. deJongeN , SchommerG , FeldmeierH , KrijgerFW , DafallaAA , BienzleU , et al. Mixed Schistosoma haematobium and S. mansoni infection: effect of different treatments on the serum level of circulating anodic antigen (CAA). Acta Tropica1990;48(1):25‐35. ">de Jonge 1990 SDN</a>, we excluded the two arms that received metrifonate and placebo respectively from the analysis. Also, we excluded one arm of the study by <a href="./references#CD000528-bbs2-0026" title="IbrahimAM . Evaluation of oxamniquine in the treatment of S. mansoni infection among Sudanese patients. East African Medical Journal1980;57(8):566‐73. ">Ibrahim 1980 SDN</a> involving participants who did not have <i>S. mansoni</i> infection and also one arm each of the trials by <a href="./references#CD000528-bbs2-0044" title="RugemalilaJB , AsilaJ , ChimbeA . Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. Journal of Tropical Medicine and Hygiene1984;87(6):231‐5. ">Rugemalila 1984 TZA</a> and <a href="./references#CD000528-bbs2-0049" title="TaylorP , MurareHM , ManomanoK . Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium . Journal of Tropical Medicine and Hygiene1988;91(1):13‐7. ">Taylor 1988 ZWE</a> that did not receive treatment from the analysis. </p> <p>The trial by <a href="./references#CD000528-bbs2-0051" title="TweyongyereR , MawaPA , EmojongNO , MpairweH , JonesFM , DuongT , et al. Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo‐controlled trial. BMC Infectious Diseases2009;9:32. TweyongyereR , MawaPA , Ngom‐WegiS , NdibazzaJ , DuongT , VennervaldBJ , et al. Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo‐controlled trial. Journal of Infectious Diseases2008;198(12):1870‐9. ">Tweyongyere 2009 UGA</a> assessing the effects of praziquantel was a nested cohort study within a larger mother and baby cohort study in which pregnant women found to be infected with <i>S. mansoni</i> were randomized to receive praziquantel or placebo. We obtained data on parasitological failure rate and clinical improvement from figures (<a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a>; <a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a>; <a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a>), but it was not possible to extract egg count data. </p> <section id="CD000528-sec-0066"> <h4 class="title">Trial setting and participants</h4> <p>The trials were conducted in Africa (n = 36), South America (n = 15; all in Brazil) and the Middle East (n = 1). Eight trials were conducted in the late 1970s, 28 in the 1980s, seven in the 1990s and only nine since the year 2000. </p> <p>Eighteen trials involved children, 12 trials recruited adults, and 22 recruited whole populations comprising children, adolescents and adults. </p> <p>Seventeen trials recruited participants from the outpatient clinics, six did not specify the setting whilst one trial (<a href="./references#CD000528-bbs2-0041" title="OmerAH . Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung1981;31(3a):605‐8. ">Omer 1981 SDN</a>) consisted of both participants identified in a field survey and those attending the hospital; two trials (<a href="./references#CD000528-bbs2-0030" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979a BRA</a>; <a href="./references#CD000528-bbs2-0031" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979b BRA</a>) involved military officers in a Barracks who became exposed to the infection during training and another trial (<a href="./references#CD000528-bbs2-0026" title="IbrahimAM . Evaluation of oxamniquine in the treatment of S. mansoni infection among Sudanese patients. East African Medical Journal1980;57(8):566‐73. ">Ibrahim 1980 SDN</a>) recruited university students on campus. The remaining 25 trials recruited participants through community surveys. </p> </section> </section> <section id="CD000528-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>For risk of bias of included studies <i>see</i> the <a href="./references#CD000528-sec-0159" title="">Characteristics of included studies</a> and summary of the risk of bias graph (<a href="#CD000528-fig-0001">Figure 1</a>) and risk of bias summary (<a href="#CD000528-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD000528-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000528-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000528-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000528-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD000528-sec-0068"> <h4 class="title">Allocation</h4> <p>We considered 16 trials as low risk of bias with regard to the generation of the randomization sequence (<a href="#CD000528-fig-0002">Figure 2</a>). In the remaining 36 trials, the methods used to generate the sequence of allocation were not described and therefore the risk of bias is unclear. </p> <p>Fourteen trials adequately described allocation concealment and had a low risk of bias. One trial did not conceal allocation (<a href="./references#CD000528-bbs2-0018" title="FernandesP , OliveiraCC . Efficacy of two regimes of praziquantel versus oxamniquine [Estudo comparativo da eficacia do praziquantel, em dois esquemas posologicos, e da oxaminiquina no tratamento da esquistossomose mansonica]. Folha Medica1986;93(5‐6):389‐93. ">Fernandes 1986 BRA</a>); and the methods were unclear in the remaining 37 trials (<a href="#CD000528-fig-0002">Figure 2</a>). </p> </section> <section id="CD000528-sec-0069"> <h4 class="title">Blinding</h4> <p>Twenty‐seven trials employed blinding and stated who was blinded. However, none described the methods of blinding. Nevertheless, the studies were considered to be at low risk of bias. One trial did not employ blinding (<a href="./references#CD000528-bbs2-0018" title="FernandesP , OliveiraCC . Efficacy of two regimes of praziquantel versus oxamniquine [Estudo comparativo da eficacia do praziquantel, em dois esquemas posologicos, e da oxaminiquina no tratamento da esquistossomose mansonica]. Folha Medica1986;93(5‐6):389‐93. ">Fernandes 1986 BRA</a>) and we therefore classed it at high risk of bias; whereas in 25 trials blinding was unclear (<a href="#CD000528-fig-0002">Figure 2</a>). </p> </section> <section id="CD000528-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>We considered the risk of bias for incomplete outcome data to be low in 17 trials (<a href="#CD000528-fig-0002">Figure 2</a>). We deemed the risk of bias to be high in 19 trials, and in the remaining 16 trials as unclear. </p> </section> <section id="CD000528-sec-0071"> <h4 class="title">Selective reporting</h4> <p>All 52 trials had low risk of selective outcome reporting (<a href="#CD000528-fig-0002">Figure 2</a>). </p> </section> <section id="CD000528-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p>Overall, 42 trials were considered to be free from other biases and the level of bias was unclear in the remaining 10 trials (<a href="#CD000528-fig-0002">Figure 2</a>). </p> </section> </section> <section id="CD000528-sec-0073"> <h3 class="title" id="CD000528-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD000528-tbl-0001"><b>Summary of findings for the main comparison</b> Praziquantel 40 mg/kg for treating <i>S. mansoni</i> infection</a>; <a href="./full#CD000528-tbl-0002"><b>Summary of findings 2</b> Oxamniquine 40 mg/kg for treating <i>S. mansoni</i> infection</a>; <a href="./full#CD000528-tbl-0003"><b>Summary of findings 3</b> Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</a>; <a href="./full#CD000528-tbl-0004"><b>Summary of findings 4</b> Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone</a> </p> <section id="CD000528-sec-0074"> <h4 class="title">Section 1. Monotherapies</h4> </section> <section id="CD000528-sec-0075"> <h4 class="title">Praziquantel</h4> <p>Nineteen trials, conducted in Africa, Brazil and the Arabian Penunsula, evaluated praziquantel. Four studies compared praziquantel with placebo, and 17 trials directly compared different dosing schedules of praziquantel with the standard dose of 40 mg/kg. </p> <section id="CD000528-sec-0076"> <h5 class="title">Analysis 1: Praziquantel versus placebo</h5> <section id="CD000528-sec-0077"> <h6 class="title">Parasitological failure</h6> <p>Two trials from Kenya and Uganda used the WHO recommended dose of 40 mg/kg. Praziquantel 40 mg/kg achieved parasitological cure in 57% and 82% of the patients respectively, compared to placebo where almost all continued to excrete eggs at one to two months (RR 3.13, 95% CI 1.03 to 9.53, two trials, 414 participants, <a href="./references#CD000528-fig-0003" title="">Analysis 1.1</a>). </p> <p>In addition, one small trial from Brazil compared three different doses of praziquantel with placebo and presented outcomes at six and 12 months. All patients given 40 mg/kg and 60 mg/kg praziquantel achieved parasitological cure at six months, while two out of five patients given 20 mg/kg and almost all those given placebo continued to excrete eggs (one trial, 40 participants, <a href="./references#CD000528-fig-0004" title="">Analysis 1.2</a>). At 12 months, reinfection was demonstrable in some of those given praziquantel (<a href="./references#CD000528-fig-0005" title="">Analysis 1.3</a>). One further trial from Brazil gave 60 mg/kg praziquantel each day for three days and achieved 100% parasitological cure at six months compared to almost complete failure with placebo (one trial, 55 participants, <a href="./references#CD000528-fig-0004" title="">Analysis 1.2</a>). </p> </section> <section id="CD000528-sec-0078"> <h6 class="title">Egg reduction</h6> <p>None of these trials reported on percentage egg reduction.</p> </section> <section id="CD000528-sec-0079"> <h6 class="title">Adverse events</h6> <p>No serious adverse events were recorded in these trials but transient dizziness and abdominal pain appeared to be more commonly reported with praziquantel than placebo (seven trials, 1255 participants, <a href="#CD000528-tbl-0006">Table 2</a>). </p> <div class="table" id="CD000528-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: Praziquantel versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Praziquantel dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0027" title="JaokoWG , MuchemiG , OguyaFO . Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East African Medical Journal1996;73(8):499‐501. ">Jaoko 1996 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events described as minor and transient.</p> <p>Dizziness: Praziquantel 36% versus 6% control</p> <p>Abdominal pain 35% versus 14 % control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0030" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979a BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg single dose</p> <p>40 mg/kg: 20 mg/kg twice in one day</p> <p>60 mg/kg: 20 mg/kg three times in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor, did not differ between intervention and placebo groups, but were not reported separately for the different dose schedules. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0031" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979b BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg/kg single dose</p> <p>60 mg/kg: 20 mg/kg three times in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor, did not differ between the two intervention groups, but were not reported separately for the two dosing schedules. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0036" title="OldsGR , KingCH , HewlettJ , OlvedaR , WuG , OumaJ , et al. Double‐blind placebo‐controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. Journal of Infectious Diseases1999;179(4):996‐1003. ">Olds 1999 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain: Praziquantel 80% versus 50% control</p> <p>Diarrhoea: Praziquantel 54% versus 25% control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0051" title="TweyongyereR , MawaPA , EmojongNO , MpairweH , JonesFM , DuongT , et al. Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo‐controlled trial. BMC Infectious Diseases2009;9:32. TweyongyereR , MawaPA , Ngom‐WegiS , NdibazzaJ , DuongT , VennervaldBJ , et al. Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo‐controlled trial. Journal of Infectious Diseases2008;198(12):1870‐9. ">Tweyongyere 2009 UGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor and transient. The authors pooled adverse events together over the intervention and placebo groups. Event rates were not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0007" title="BranchiniML , PedroR J de , DiasLC , DeberaldiniER . Double‐blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):315‐21. ">Branchini 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.2 to 51.6 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Dizziness: Praziquantel 46.9% (control group not reported).</p> <p>Abdominal pain: Praziquantel 24.5% versus 17.6% control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0019" title="FerrariML , CoelhoPM , AntunesCM , TavaresCA , daCunhaAS . Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bulletin of the World Health Organization2003;81(3):190‐6. ">Ferrari 2003 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180 mg/kg: 60 mg/kg once daily for three days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Events were mostly headache, dizziness, drowsiness and abdominal pain. Patients from the placebo group also reported having abdominal pain and drowsiness. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0080"> <h5 class="title">Analyses 2 and 3: Lower doses praziquantel versus 40 mg/kg</h5> <section id="CD000528-sec-0081"> <h6 class="title">Parasitological failure</h6> <p>Lower doses (20 mg/kg to 30 mg/kg) have been evaluated in Zimbabwe, Burundi, Sudan and Brazil. Compared to 40 mg/kg, parasitological failure at one month was more than double with the 20 mg/kg dose, and 50% higher with the 30 mg/kg dose (20 mg/kg: RR 2.23, 95% CI 1.64 to 3.02, two trials, 341 participants; 30 mg/kg: RR 1.52, 95% CI 1.15 to 2.01, three trials, 521 participants; <a href="./references#CD000528-fig-0006" title="">Analysis 2.1</a>). Follow‐up at three months (<a href="./references#CD000528-fig-0007" title="">Analysis 2.2</a>) and at six to 12 months showed a similar pattern (<a href="./references#CD000528-fig-0008" title="">Analysis 2.3</a>). </p> </section> <section id="CD000528-sec-0082"> <h6 class="title">Egg reduction</h6> <p>In one trial from Brazil evaluating 30 mg/kg versus 40 mg/kg, geometric mean egg reductions were high in both groups, at six months (92.5% versus 97.7%, statistical significance not reported (one trial, 138 participants, <a href="./references#CD000528-fig-0009" title="">Analysis 2.4</a>)). </p> </section> <section id="CD000528-sec-0083"> <h6 class="title">Symptom resolution</h6> <p>One trial compared a lower dose of praziquantel at 20 mg/kg with 40 mg/kg and showed no difference in resolving symptoms at three, six, 12 and 24 months of follow‐up: diarrhoea (one trial, 44 participants, <a href="./references#CD000528-fig-0012" title="">Analysis 3.3</a>), blood in stool (one trial, 37 participants, <a href="./references#CD000528-fig-0014" title="">Analysis 3.5</a>), hepatomegaly (one trial, 55 participants, <a href="./references#CD000528-fig-0016" title="">Analysis 3.7</a>) and splenomegaly (one trial, 73 participants, <a href="./references#CD000528-fig-0018" title="">Analysis 3.9</a>), except one study that showed that 40 mg/kg significantly improved abdominal pain at one month (RR 0.59, 95% CI 0.36 to 0.98, one trial, 169 participants, <a href="./references#CD000528-fig-0010" title="">Analysis 3.1</a>). </p> <p>Two trials compared 30 mg/kg with 40 mg/kg and did not show any difference in resolving symptoms at one, three, six, 12 and 24 months of follow‐up: abdominal pain (two trials, 318 participants, <a href="./references#CD000528-fig-0011" title="">Analysis 3.2</a>), diarrhoea (two trials, 48 participants, <a href="./references#CD000528-fig-0013" title="">Analysis 3.4</a>), blood in stool (two trials, 82 participants, <a href="./references#CD000528-fig-0015" title="">Analysis 3.6</a>), hepatomegaly (two trials, 109 participants, <a href="./references#CD000528-fig-0017" title="">Analysis 3.8</a>) and splenomegaly (two trials, 122 participants, <a href="./references#CD000528-fig-0019" title="">Analysis 3.10</a>). </p> </section> <section id="CD000528-sec-0084"> <h6 class="title">Adverse events</h6> <p>In the three trials reporting adverse events, consistent differences in frequency or severity between 20, 30 and 40 mg/kg doses have not been shown (three trials, 319 participants, <a href="#CD000528-tbl-0007">Table 3</a>). </p> <div class="table" id="CD000528-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: praziquantel (lower dose) versus 40 mg/kg</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0030" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979a BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg single dose</p> <p>40 mg/kg: 20 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Minor adverse events, did not differ between intervention and control groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0032" title="KatzN . Clinical trials with praziquantel in schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1981;23(2):72‐8. ">Katz 1981 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Minor adverse events (lower dose first):</p> <p>Abdominal pain: 42.6% versus 44.4%</p> <p>Giddiness: 14.9% versus 26.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0041" title="OmerAH . Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung1981;31(3a):605‐8. ">Omer 1981 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Diarrhoea, vomiting, nausea and abdominal pain were commonly reported but these were transient. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0085"> <h5 class="title">Analysis 4: Higher doses praziquantel versus 40 mg/kg</h5> <section id="CD000528-sec-0086"> <h6 class="title">Parasitological failure</h6> <p>Higher doses (50 mg/kg to 60 mg/kg) have been evaluated in Brazil (three trials), Mauritania, Senegal and Tanzania. Compared to 40 mg/kg, parasitological failure has not been shown to be improved with higher doses at one month (five trials, 783 participants, <a href="./references#CD000528-fig-0020" title="">Analysis 4.1</a>). </p> </section> <section id="CD000528-sec-0087"> <h6 class="title">Egg reduction</h6> <p>Among participants still excreting eggs, percentage egg reductions were similar in both groups at one month (four trials, 786 participants, <a href="./references#CD000528-fig-0023" title="">Analysis 4.4</a>). </p> </section> <section id="CD000528-sec-0088"> <h6 class="title">Adverse events</h6> <p>One multi‐country trial reported adverse events and recorded one serious event (a seizure) with the higher dose. At the trial site in Brazil, non‐severe adverse events appeared to be more common with the higher dose but this was not seen consistently at the trial sites in Mauritania or Tanzania (one trial, 653 participants, see <a href="#CD000528-tbl-0008">Table 4</a>). </p> <div class="table" id="CD000528-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: praziquantel (higher dose) versus 40 mg/kg</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0037" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse event. Minor adverse events (highest dose first):</p> <p>Abdominal pain: 48 versus 47.9%</p> <p>Nausea: 20.4% versus 18.4%</p> <p>Dizziness: 20.4% versus 11.2%</p> <p>Headache: 14.3% versus 12.2%</p> <p>Vomiting: 11.2% versus 5.19%</p> <p>Diarrhoea: 8.2% versus 4.1%</p> <p>Rarely sleepiness was also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0038" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 MRT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One incidence of serious event was recorded in the higher dose (60 mg/kg). The rest of the events were minor. Transient dizziness, abdominal pain, diarrhoea, vomiting and headache were commonly reported (highest dose first): </p> <p>Dizziness: 77.8% versus 9.7%</p> <p>Abdominal pain:79.6% versus 71.0%</p> <p>Diarrhoea: 41.9% versus 49.5%</p> <p>Vomiting: 10.7% versus 32.3%</p> <p>Headache: 9.7% versus 14.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0039" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events (highest dose first):</p> <p>Abdominal pain: 88.9% versus 83.8%</p> <p>Diarrhoea: 47.4% versus 49.3%</p> <p>Nausea: 26.7% versus 30.9%</p> <p>Headache: 14.1% versus 9.6%</p> <p>Vomiting: 11.1% versus 16.9%</p> <p>Dizziness: 6.7% versus 9.6%</p> <p>Fever: 0% versus 1.5%.</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0089"> <h5 class="title">Analysis 5: Split dose praziquantel versus 40 mg/kg in a single dose</h5> <p>Splitting 40 mg/kg into divided doses given on the same day was evaluated in the 1980s in three trials in Sudan. </p> <section id="CD000528-sec-0090"> <h6 class="title">Parasitological failure</h6> <p>At one month, two trials did not demonstrate a statistically significant benefit with the split dose regimen compared to a single 40 mg/kg dose (two trials, 525 participants, <a href="./references#CD000528-fig-0024" title="">Analysis 5.1</a>), but showed benefit at three months (RR 0.31, 95% CI 0.18 to 0.53, two trials, 516 participants, <a href="./references#CD000528-fig-0025" title="">Analysis 5.2</a>). </p> <p>One further small trial, only reported the outcome at six months and found no difference (one trial, 64 participants, <a href="./references#CD000528-fig-0026" title="">Analysis 5.3</a>). </p> </section> <section id="CD000528-sec-0091"> <h6 class="title">Egg reduction</h6> <p>In the only trial reporting egg count, the mean percent reduction at one month was higher with the divided dose but statistical significance was not reported (divided dose 93.2% versus single dose 86.5%, one trial, 350 participants, <a href="./references#CD000528-fig-0027" title="">Analysis 5.4</a>). </p> </section> <section id="CD000528-sec-0092"> <h6 class="title">Adverse events</h6> <p>No serious adverse events were reported in these trials. Only one trial reported the frequency of adverse events in each treatment group (<a href="./references#CD000528-bbs2-0028" title="KardamanMW , AminMA , FenwickA , CheesmondAK , DixonHG . A field trial using praziquantel (Biltricide) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan. Annals of Tropical Medicine and Parasitology1983;77(3):297‐304. ">Kardaman 1983 SDN</a>). Mild abdominal pain and diarrhoea were less common when the dose was given in divided doses but vomiting was more common (one trial, 350 participants, <a href="#CD000528-tbl-0009">Table 5</a>). </p> <div class="table" id="CD000528-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: praziquantel (40 mg/kg in a divided dose) versus praziquantel (40 mg/kg) single dose</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0028" title="KardamanMW , AminMA , FenwickA , CheesmondAK , DixonHG . A field trial using praziquantel (Biltricide) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan. Annals of Tropical Medicine and Parasitology1983;77(3):297‐304. ">Kardaman 1983 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg: 20 mg/kg twice in a day</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Events were transient (divided dose first): Abdominal pain: 13.5% versus 24.6% </p> <p>Vomiting: 7.6% versus 4%</p> <p>Diarrhoea: 7.6% versus 12.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0041" title="OmerAH . Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung1981;31(3a):605‐8. ">Omer 1981 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg: 20 mg/kg twice in a day</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events.</p> <p>Adverse events were transient and required no additional intervention.</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0093"> <h5 class="title">Analysis 6: Other praziquantel dosing regimens</h5> <p>Several trials from Brazil have evaluated higher praziquantel dosing regimens with 30 mg/kg to 60 mg/kg given for up to six days (see <a href="./references#CD000528-fig-0028" title="">Analysis 6.1</a>). It is difficult to draw conclusions from these studies as the comparator dose is also a non‐standard regimen, but one trial did demonstrate improved parasitological cure rates with prolonged courses given over three to six days compared to courses lasting one day. </p> <section id="CD000528-sec-0094"> <h6 class="title">Adverse events</h6> <p>No serious adverse events were reported in these trials, events were mainly transient dizziness and nausea (one trial, 79 participants, <a href="#CD000528-tbl-0010">Table 6</a>). </p> <div class="table" id="CD000528-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events: praziquantel alternative dosing (Brazil)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0010" title="daCunhaAS , CançadoJR , deRezendeGL . Therapeutical evaluation of different dose regimens of praziquantel in schistosomiasis mansoni, based on the quantitative oogram technique. Revista do Instituto de Medicina Tropical de São Paulo1987;29(5):295‐304. ">da Cunha 1987 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180 mg/kg: 30 mg/kg twice daily for three days</p> <p>180 mg/kg: 30 mg/kg daily for six days</p> <p>120 mg/kg: 30 mg/kg twice daily for two days</p> <p>60 mg/kg: 30 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events.</p> <p>Minor and transient events (highest dose first):</p> <p>Dizziness: 65%, 15%, 45% versus 15%</p> <p>Nausea: 55%, 15, 20% versus 20%</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section id="CD000528-sec-0095"> <h4 class="title">Oxamniquine</h4> <p>Seventeen trials evaluated oxamniquine, with the most recent conducted in the 1980s. Oxamniquine has since fallen out of use in favour of praziquantel. Four trials compared oxamniquine with placebo and 12 trials directly compared different dosing schedules of oxamniquine in different geographical locations in Africa and Brazil. The most common comparator dose was 40 mg/kg. </p> <section id="CD000528-sec-0096"> <h5 class="title">Analysis 7: Oxamniquine versus placebo</h5> <section id="CD000528-sec-0097"> <h6 class="title">Parasitological failure</h6> <p>In two trials in Brazil, 20 mg/kg was significantly superior to placebo at longer timepoints (RR 3.68, 95% CI 2.53 to 5.36, two trials, 146 participants, <a href="./references#CD000528-fig-0033" title="">Analysis 7.2</a>). In two trials from Ethiopia, oxamniquine achieved parasitological cure rates of &gt; 75% with 30, 40, and 60 mg/kg at three to four months, compared to placebo where almost all participants continued to excrete eggs (30 mg/kg: RR 4.34, 95% CI 2.47 to 7.65, two trials, 82 participants; 40 mg/kg: RR 8.74, 95% CI 3.74 to 20.43, two trials, 82 participants; 60 mg/kg: RR 19.38, 95% CI 5.79 to 64.79, two trials, 89 participants; <a href="./references#CD000528-fig-0032" title="">Analysis 7.1</a>). </p> </section> <section id="CD000528-sec-0098"> <h6 class="title">Egg reduction</h6> <p>Among those still excreting eggs at three to four months, two trials from Ethiopia reported significant reductions in egg numbers in those given oxamniquine (68.1% to 100%), compared to increases of 59 to 80.6% in the placebo groups (two trials, 227 participants, <a href="./references#CD000528-fig-0034" title="">Analysis 7.3</a>). </p> </section> <section id="CD000528-sec-0099"> <h6 class="title">Adverse events</h6> <p>No serious adverse events were reported in these trials. Dizziness was more commonly reported with oxamniquine than placebo but is described as transient, with most resolving within 24 hours (five trials, 425 participants, <a href="#CD000528-tbl-0011">Table 7</a>). </p> <div class="table" id="CD000528-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events: oxamniquine versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Oxamniquine dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0003" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. East African Medical Journal1984;61(8):632‐6. ">Ayele 1984 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for two days</p> <p>40 mg/kg: 10 mg/kg twice daily for two days</p> <p>30 mg/kg: 15 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor and transient.</p> <p>Dizziness: Oxamniquine (15 mg/kg BD for 2 days) 50% versus 38.9% (10 mg/kg BD for two days) versus 30% control. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0004" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. East African Medical Journal1986;63(4):291‐4. ">Ayele 1986 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for two days</p> <p>40 mg/kg: 20 mg/kg twice in one day</p> <p>30 mg/kg: 15 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All the doses were well tolerated and accepted. Dizziness was the most frequently reported complaint, but this was mild and transient. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0034" title="LambertucciJR , GrecoDB , PedrosoER , daCosta RochaMO , SalazarHM , deLimaDP . A double blind trial with oxamniquine in chronic schistosomiasis mansoni. Transactions of the Royal Society of Tropical Medicine and Hygiene1982;76(6):751‐5. ">Lambertucci 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor and transient.</p> <p>Dizziness: Oxamniquine 14.6% versus 2.8% control</p> <p>Nausea: Oxamniquine 14.6% versus 5.6% control.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0007" title="BranchiniML , PedroR J de , DiasLC , DeberaldiniER . Double‐blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):315‐21. ">Branchini 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were few and minor. Dizziness: Oxamniquine 44.2% (control not reported)</p> <p>Abdominal pain: Oxamniquine 11.5% versus 17.6% control.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0019" title="FerrariML , CoelhoPM , AntunesCM , TavaresCA , daCunhaAS . Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bulletin of the World Health Organization2003;81(3):190‐6. ">Ferrari 2003 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg: 10 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events.</p> <p>Adverse events were mild, mostly headache, dizziness, drowsiness and abdominal pain. Patients from the placebo group also had abdominal pain and drowsiness. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0100"> <h5 class="title">Analyses 8 and 9: Lower doses oxamniquine versus 40 mg/kg</h5> <p>Lower doses of oxamniquine (20 to 30 mg/kg) have been compared to 40 mg/kg in Ethiopia (two trials), Sudan (two trials), Zimbabwe (two trials), Burundi and Malawi. </p> <section id="CD000528-sec-0101"> <h6 class="title">Parasitological failure</h6> <p>Compared to 40 mg/kg, both 20 mg/kg and 30 mg/kg of oxamniquine resulted in significantly more parasitological failures at one month (20 mg/kg: RR 3.78, 95% CI 2.05 to 6.99, two trials, 190 participants; 30 mg/kg: RR 1.78, 95% CI 1.15 to 2.75, four trials, 268 participants, <a href="./references#CD000528-fig-0035" title="">Analysis 8.1</a>), and at three to four months (20 mg/kg: RR 2.28, 95% CI 1.40 to 3.71, three trials, 209 participants; 30 mg/kg: RR 1.64, 95% CI 1.10 to 2.43, seven trials, 373 participants, <a href="./references#CD000528-fig-0036" title="">Analysis 8.2</a>). </p> <p>At later time points, no statistically significant differences were shown: six months (20 mg/kg: two trials, 163 participants; 30 mg/kg: three trials, 214 participants, <a href="./references#CD000528-fig-0037" title="">Analysis 8.3</a>) and 12 months (20 mg/kg: two trials, 144 participants; 30 mg/kg: one trial, 77 participants, <a href="./references#CD000528-fig-0038" title="">Analysis 8.4</a>). </p> </section> <section id="CD000528-sec-0102"> <h6 class="title">Egg reduction</h6> <p>Percent egg reduction was evaluated in six of these trials and both lower dose and 40 mg/kg showed a wide range of benefit at one, three and six months: lower dose (57.1% to 99%) and 40 mg/kg (42.7 to 100%) (six trials, 878 participants, <a href="./references#CD000528-fig-0039" title="">Analysis 8.5</a>). </p> </section> <section id="CD000528-sec-0103"> <h6 class="title">Symptom resolution</h6> <p>One trial compared a lower dose of 20 mg/kg oxamniquine with 40 mg/kg and did not find any difference between the two doses in resolving symptoms at one, three, six, 12 and 24 months of follow‐up: abdominal pain (one trial, 95 participants, <a href="./references#CD000528-fig-0040" title="">Analysis 9.1</a>), diarrhoea (one trial, 16 participants, <a href="./references#CD000528-fig-0042" title="">Analysis 9.3</a>), blood in stool (one trial, 85 participants, <a href="./references#CD000528-fig-0044" title="">Analysis 9.5</a>), hepatomegaly (one trial, 64 participants, <a href="./references#CD000528-fig-0046" title="">Analysis 9.7</a>) and splenomegaly (one trial, 69 participants, <a href="./references#CD000528-fig-0048" title="">Analysis 9.9</a>). </p> <p>Also, 30 mg/kg did not show any difference statistically compared with 40 mg/kg in resolving symptoms at one, three, six, 12 and 24 months of follow‐up: abdominal pain (one trial, 95 participants, <a href="./references#CD000528-fig-0041" title="">Analysis 9.2</a>), diarrhoea (one trial, 15 participants, <a href="./references#CD000528-fig-0043" title="">Analysis 9.4</a>), blood in stool (one trial, 41 participants, <a href="./references#CD000528-fig-0045" title="">Analysis 9.6</a>), hepatomegaly (one trial, 51 participants, <a href="./references#CD000528-fig-0047" title="">Analysis 9.8</a>) and splenomegaly (one trial, 54 participants, <a href="./references#CD000528-fig-0049" title="">Analysis 9.10</a>). </p> </section> <section id="CD000528-sec-0104"> <h6 class="title">Adverse events</h6> <p>Six trials from Ethiopia (two trials), and one trial each from Malawi, Sudan, Zambia and Zimbabwe assessed adverse events and reported no serious events. Dizziness was most commonly reported, but the event rate and severity did not differ between doses (six trials, 508 participants, <a href="#CD000528-tbl-0012">Table 8</a>). </p> <div class="table" id="CD000528-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: oxamniquine (lower dose) versus 40 mg/kg</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0003" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. East African Medical Journal1984;61(8):632‐6. ">Ayele 1984 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg: 15 mg/kg twice in one day.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events were reported. Transient dizziness and nausea were commonly reported (lower dose first): </p> <p>Dizziness: 38.9% versus 42%</p> <p>Nausea: 22.2% versus 26.3%</p> <p>A few mild headaches and abdominal pain were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0004" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. East African Medical Journal1986;63(4):291‐4. ">Ayele 1986 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg:15 mg/kg twice in one day.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All doses were well tolerated and no serious event was recorded. Dizziness was more commonly reported, but this was transient. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0013" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976b ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg: 5 x 2 mg/kg daily for two days</p> <p>30 mg/kg: 7.5 x 2 mg/kg daily for two days.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events were recorded. Transient dizziness was more commonly reported and very rarely headache, nausea, and vomiting. Adverse events did not differ between dose. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0024" title="GuptaKK . Schistosoma mansoni treatment with oral oxamniquine in Zambia. East African Medical Journal1984;61(8):641‐4. ">Gupta 1984 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg:15 mg/kg twice in one day</p> <p>40 mg/kg: 10 mg/kg twice daily for two days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious events were reported. Adverse events were mainly dizziness and nausea, but were minor and transient (lower dose first): </p> <p>Dizziness: 20% versus 25%</p> <p>Nausea: 15% versus 30%</p> <p>A few events of vomiting, headache and abdominal pain were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0040" title="OmerAH . Oxamniquine for treating Schistosoma mansoni infection in Sudan. British Medical Journal1978;2(6131):163‐5. ">Omer 1978 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg: 15 mg/kg twice in one day</p> <p>40 mg/kg: 20 mg/kg daily for 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events were recorded. Asthenia (weakness) was reported among a few receiving 40 mg/kg, but this did not require additional intervention. Transient dizziness was more commonly reported (lower dose first) </p> <p>Dizziness: 3% versus 8%</p> <p>Minor abdominal pain, headache and vomiting also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0050" title="TeesdaleCH , ChitsuloL , PughRN . Oxamniquine dosage in Malawi. East African Medical Journal1984;61(1):40‐4. ">Teesdale 1984 MWI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg single dose</p> <p>30 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Noserious adverse events were recorded. Transient dizziness, nausea and vomiting were most commonly reported. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0105"> <h5 class="title">Analysis 10: Higher doses oxamniquine versus 40 mg/kg</h5> <p>Higher doses of oxamniquine (50 mg/kg to 60 mg/kg) have been compared to 40 mg/kg in six trials from three countries; Sudan (three trials), Ethiopia (two trials) and Zambia (one trial). </p> <section id="CD000528-sec-0106"> <h6 class="title">Parasitological failure</h6> <p>Higher doses of oxamniquine have not shown consistent statistically significant benefits over 40 mg/kg at one month (five trials, 349 participants, <a href="./references#CD000528-fig-0050" title="">Analysis 10.1</a>), at three to four months (six trials, 397 participants, <a href="./references#CD000528-fig-0051" title="">Analysis 10.2</a>), or six months (two trials, 177 participants, <a href="./references#CD000528-fig-0052" title="">Analysis 10.3</a>). </p> <p>Losses to follow‐up were high in the trial investigating 50 mg/kg, reaching 76.9% at three months, and heterogeneity between the trials was significant (I<sup>2</sup>= 64% to 82%). </p> </section> <section id="CD000528-sec-0107"> <h6 class="title">Egg reduction</h6> <p>Seven trials evaluated egg count and reported a wide range of percent mean reductions among those not cured at one month (86% to 100% versus 56% to 99.1%, four trials, 561 participants, <a href="./references#CD000528-fig-0053" title="">Analysis 10.4</a>), three to four months (82% to 100% versus 42% to 100%, six trials, 791 participants, <a href="./references#CD000528-fig-0053" title="">Analysis 10.4</a>) and six months (62.% to 100% versus 75% to 100%, four trials, 561 participants, <a href="./references#CD000528-fig-0053" title="">Analysis 10.4</a>). </p> </section> <section id="CD000528-sec-0108"> <h6 class="title">Adverse events</h6> <p>In five trials reporting adverse events, no serious events were recorded. Dizziness and nausea were most commonly reported, but these were transient and did not require additional interventions (one trial, 482 participants, <a href="#CD000528-tbl-0013">Table 9</a>). </p> <div class="table" id="CD000528-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: oxamniquine (higher dose) versus 40 mg/kg</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0003" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. East African Medical Journal1984;61(8):632‐6. ">Ayele 1984 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for two days</p> <p>40 mg/kg: 10 mg/kg twice daily for two days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse event was recorded. Dizziness and nausea were commonly reported but these were transient (higher dose first): </p> <p>Dizziness: 50% versus 42%</p> <p>Nausea: 11% versus 26.3%</p> <p>A few mild headaches and abdominal pain were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0004" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. East African Medical Journal1986;63(4):291‐4. ">Ayele 1986 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for 2 days</p> <p>40 mg/kg: 20 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events were recorded. Dizziness was more commonly reported, but this was transient and did not differ between dose. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0024" title="GuptaKK . Schistosoma mansoni treatment with oral oxamniquine in Zambia. East African Medical Journal1984;61(8):641‐4. ">Gupta 1984 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for two days</p> <p>40 mg/kg: 10 mg/kg twice for daily for two days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious events were reported. Transient dizziness and nausea were more commonly reported (higher dose first): </p> <p>Dizziness: 40% versus 25%</p> <p>Nausea: 25% versus 30%</p> <p>A few events of vomiting, headache and abdominal pain were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0040" title="OmerAH . Oxamniquine for treating Schistosoma mansoni infection in Sudan. British Medical Journal1978;2(6131):163‐5. ">Omer 1978 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for 2 days</p> <p>40 mg/kg: 20 mg/kg daily for 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events was recorded. Transient dizziness was more commonly reported (higher dose first): </p> <p>Dizziness: 15% versus 8%</p> <p>Few minor abdominal pain, headache and vomiting were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0050" title="TeesdaleCH , ChitsuloL , PughRN . Oxamniquine dosage in Malawi. East African Medical Journal1984;61(1):40‐4. ">Teesdale 1984 MWI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events was recorded. Transient dizziness, nausea and vomiting were most commonly reported and did not differ between dose. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0109"> <h5 class="title">Analyses 11 and 12: Other oxamniquine dosing regimes</h5> <p>Nine additional trials compared 30 mg/kg oxamniquine with higher and lower doses in Ethiopia (three trials), Zimbabwe (two trials), Burundi (one trial), Nigeria (one trial), Sudan (one trial) and Zambia (one trial). </p> <section id="CD000528-sec-0110"> <h6 class="title">Lower doses versus 30 mg/kg</h6> <p>Compared to 30 mg/kg, parasitological failure was higher with 15 mg/kg to 20 mg/kg oxamniquine at one month (RR 1.77, 95% CI 1.14 to 2.74, two trials, 230 participants), and at three to four months (RR 2.16, 95% CI 1.40 to 3.32, four trials, 249 participants, <a href="./references#CD000528-fig-0054" title="">Analysis 11.1</a>). </p> <p>At later follow‐up times, no statistically significant difference were demonstrated (six months: two trials, 179 participants; and 12 months: one trial, 95 participants, <a href="./references#CD000528-fig-0054" title="">Analysis 11.1</a>). </p> </section> <section id="CD000528-sec-0111"> <h6 class="title">Higher doses versus 30 mg/kg</h6> <p>Compared to 30 mg/kg, 60 mg/kg oxamniquine resulted in significantly fewer parasitological failures at one month (RR 0.04, 95% CI 0.01 to 0.26, two trials, 175 participants, <a href="./references#CD000528-fig-0055" title="">Analysis 12.1</a>), at three to four months (RR 0.17, 95% CI 0.07 to 0.39, four trials, 265 participants, <a href="./references#CD000528-fig-0056" title="">Analysis 12.2</a>) and at six months (RR 0.17, 95% CI 0.06 to 0.50, two trials, 157 participants, <a href="./references#CD000528-fig-0057" title="">Analysis 12.3</a>). </p> <p>No statistically significant differences were seen between 50 mg/kg and 30 mg/kg at one month (one trial, 36 participants, <a href="./references#CD000528-fig-0055" title="">Analysis 12.1</a>) or at three to four months (two trials, 53 participants, <a href="./references#CD000528-fig-0056" title="">Analysis 12.2</a>). </p> </section> </section> <section id="CD000528-sec-0112"> <h5 class="title">Analysis 13: Praziquantel (40 mg/kg) versus oxamniquine</h5> <p>Eleven trials from different geographical locations directly compared various doses of oxamniquine with praziquantel 40 mg/kg. Dosing schedules commonly applied across different locations are reported in <a href="#CD000528-tbl-0014">Table 10</a>. The most recent trial, from Sudan, was published in 1990. </p> <div class="table" id="CD000528-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Commonly used dosing schedule of oxamniquine and praziquantel according to location</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Location (country)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Oxamniquine (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Praziquantel (mg/kg)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>South America</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0007" title="BranchiniML , PedroR J de , DiasLC , DeberaldiniER . Double‐blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):315‐21. ">Branchini 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0009" title="daCunhaAS , PedrosaRC . Double‐blind therapeutical evaluation based on the quantitative oogram technique, comparing praziquantel and oxamniquine in human Schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1986;28(5):337‐51. ">da Cunha 1986 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0010" title="daCunhaAS , CançadoJR , deRezendeGL . Therapeutical evaluation of different dose regimens of praziquantel in schistosomiasis mansoni, based on the quantitative oogram technique. Revista do Instituto de Medicina Tropical de São Paulo1987;29(5):295‐304. ">da Cunha 1987 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60, 120, 180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0011" title="daSilvaLC , ZeituneJM , Rosa‐EidLM , LimaDM , AntonelliRH , ChristoCH , et al. Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine. Revista do Instituto de Medicina Tropical de São Paulo1986;28(3):174‐80. ">da Silva 1986 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0018" title="FernandesP , OliveiraCC . Efficacy of two regimes of praziquantel versus oxamniquine [Estudo comparativo da eficacia do praziquantel, em dois esquemas posologicos, e da oxaminiquina no tratamento da esquistossomose mansonica]. Folha Medica1986;93(5‐6):389‐93. ">Fernandes 1986 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0019" title="FerrariML , CoelhoPM , AntunesCM , TavaresCA , daCunhaAS . Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bulletin of the World Health Organization2003;81(3):190‐6. ">Ferrari 2003 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0030" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979a BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20, 40, 60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0031" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979b BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0032" title="KatzN . Clinical trials with praziquantel in schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1981;23(2):72‐8. ">Katz 1981 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 30, 50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0033" title="KatzN , RochaRS . Double‐blind clinical trial comparing praziquantel with oxamniquine in schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):310‐4. ">Katz 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0034" title="LambertucciJR , GrecoDB , PedrosoER , daCosta RochaMO , SalazarHM , deLimaDP . A double blind trial with oxamniquine in chronic schistosomiasis mansoni. Transactions of the Royal Society of Tropical Medicine and Hygiene1982;76(6):751‐5. ">Lambertucci 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0042" title="QueirozLC , DrummondSC , MatosML , PaivaMB , BatistaTS , KansaonAZ , et al. Comparative randomised trial of high and conventional doses of praziquantel in the treatment of schistosomiasis mansoni. Memorias do Instituto Oswaldo Cruz2010;105(4):445‐8. ">Queiroz 2010 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50, 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0043" title="Rezende GLde . Survey on the clinical results achieved in Brazil comparing praziquantel and oxamniquine in the treatment of S. mansoni schistosomiasis. Revista do Instituto de Medicina Tropical de São Paulo1985;27(6):328‐68. ">Rezende 1985 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0052" title="ZwingenbergerK , QueirozJA , PoggenseeU , AlencarJE , ValdegunasJ , EsmeraldaF , et al. Efficacy of oxamniquine, praziquantel and a combination of both drugs in schistosomiasis mansoni in Brazil. Revista do Instituto de Medicina Tropical de São Paulo1987;29(5):305‐11. ">Zwingenberger 1987 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>North Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0017" title="DoehringE , EhrichJH , VesterU , FeldmeierH , PoggenseeU , BrodehlJ . Proteinuria, hematuria, and leukocyturia in children with mixed urinary and intestinal schistosomiasis. Kidney International1985;28(3):520‐5. DoehringE , PoggenseeU , FeldmeierH . The effect of metrifonate in mixed Schistosoma haematobium and Schistosoma mansoni infections in humans. American Journal of Tropical Medicine and Hygiene1986;35(2):323‐9. FeldmeierH , GastlGA , PoggenseeU , KortmannC , DaffallaAA , PeterHH . Relationship between intensity of infection and immunomodulation in human schistosomiasis. II. NK cell activity and in vitro lymphocyte proliferation. Clinical and Experimental Immunology1985;60(2):234‐40. FeldmeierH , Nogueira‐QueirozJA , Peixoto‐QueirozMA , DoehringE , DessaintJP , deAlencarJE , et al. Detection and quantification of circulating antigen in schistosomiasis by monoclonal antibody. II. The quantification of circulating antigens in human schistosomiasis mansoni and haematobium: relationship to intensity of infection and disease status. Clinical and Experimental Immunology1986;65(2):232‐43. deJongeN , SchommerG , FeldmeierH , KrijgerFW , DafallaAA , BienzleU , et al. Mixed Schistosoma haematobium and S. mansoni infection: effect of different treatments on the serum level of circulating anodic antigen (CAA). Acta Tropica1990;48(1):25‐35. ">de Jonge 1990 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0025" title="HomeidaMM , EltomIA , SulaimanSM , AliHM , BennettJL . Tolerance of two brands of praziquantel. Lancet1989;334(8659):391. ">Homeida 1989 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0026" title="IbrahimAM . Evaluation of oxamniquine in the treatment of S. mansoni infection among Sudanese patients. East African Medical Journal1980;57(8):566‐73. ">Ibrahim 1980 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0028" title="KardamanMW , AminMA , FenwickA , CheesmondAK , DixonHG . A field trial using praziquantel (Biltricide) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan. Annals of Tropical Medicine and Parasitology1983;77(3):297‐304. ">Kardaman 1983 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0040" title="OmerAH . Oxamniquine for treating Schistosoma mansoni infection in Sudan. British Medical Journal1978;2(6131):163‐5. ">Omer 1978 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0041" title="OmerAH . Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung1981;31(3a):605‐8. ">Omer 1981 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0005" title="BarakatR , ElmorshedyH , FenwickA . Efficacy of myrrh in the treatment of human schistosomiasis mansoni. American Journal of Tropical Medicine and Hygiene2005;73(2):365‐7. ">Barakat 2005 EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0006" title="BotrosS , SayedH , El‐DusokiH , SabryH , RabieI , El‐GhannamM , et al. Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni‐infected school children and households. American Journal of Tropical Medicine and Hygiene2005;72(2):119‐23. ">Botros 2005 EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0035" title="MetwallyA , BennettJ , BotrosS , EbeidF , elattar GelD . Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. Pharmacological Research1995;31(1):53‐9. ">Metwally 1995 EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>East Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0003" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. East African Medical Journal1984;61(8):632‐6. ">Ayele 1984 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethiopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0004" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. East African Medical Journal1986;63(4):291‐4. ">Ayele 1986 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethiopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0027" title="JaokoWG , MuchemiG , OguyaFO . Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East African Medical Journal1996;73(8):499‐501. ">Jaoko 1996 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kenya</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0036" title="OldsGR , KingCH , HewlettJ , OlvedaR , WuG , OumaJ , et al. Double‐blind placebo‐controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. Journal of Infectious Diseases1999;179(4):996‐1003. ">Olds 1999 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kenya</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0048" title="TaddeseK , ZeinZA . Comparison between the efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infections on a sugar estate in Ethiopia. Annals of Tropical Medicine and Parasitology1988;82(2):175‐80. ">Taddese 1988 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethiopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15, 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0050" title="TeesdaleCH , ChitsuloL , PughRN . Oxamniquine dosage in Malawi. East African Medical Journal1984;61(1):40‐4. ">Teesdale 1984 MWI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malawi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0044" title="RugemalilaJB , AsilaJ , ChimbeA . Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. Journal of Tropical Medicine and Hygiene1984;87(6):231‐5. ">Rugemalila 1984 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tanzania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0051" title="TweyongyereR , MawaPA , EmojongNO , MpairweH , JonesFM , DuongT , et al. Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo‐controlled trial. BMC Infectious Diseases2009;9:32. TweyongyereR , MawaPA , Ngom‐WegiS , NdibazzaJ , DuongT , VennervaldBJ , et al. Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo‐controlled trial. Journal of Infectious Diseases2008;198(12):1870‐9. ">Tweyongyere 2009 UGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uganda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>West Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0045" title="ShafeiAZ . A preliminary report on the treatment of intestinal schistosomiasis with oxamniquine. Journal of Tropical Medicine and Hygiene1979;82(1):18‐20. ">Shafei 1979 NGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nigeria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15, 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0016" title="DeClercqD , VercruysseJ , VerleP , KongsA , DiopM . What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections?. Tropical Medicine and International Health2000;5(10):744‐6. ">De Clercq 2000 SEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0023" title="GuisseF , PolmanK , StelmaFF , MbayeA , TallaI , NiangM , et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. American Journal of Tropical Medicine and Hygiene1997;56(5):511‐4. ">Guisse 1997 SEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40, 60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0046" title="StelmaFF , SallS , DaffB , SowS , NiangM , GryseelsB . Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. Journal of Infectious Diseases1997;176(1):304‐7. ">Stelma 1997 SEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Central Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burundi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20, 30, 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burundi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20, 30, 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Southern Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0024" title="GuptaKK . Schistosoma mansoni treatment with oral oxamniquine in Zambia. East African Medical Journal1984;61(8):641‐4. ">Gupta 1984 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zambia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0047" title="SukwaTY . A community‐based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. Annals of Tropical Medicine and Parasitology1993;87(2):185‐94. ">Sukwa 1993 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zambia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0012" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976a ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zimbabwe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15, 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0013" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976b ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zimbabwe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0014" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976c ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zimbabwe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0049" title="TaylorP , MurareHM , ManomanoK . Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium . Journal of Tropical Medicine and Hygiene1988;91(1):13‐7. ">Taylor 1988 ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zimbabwe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10, 20, 30, 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Middle East</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0002" title="Al‐AskaAK , Al‐MoflehIA , Al‐RashedR , HafezMA , Al‐NozhaM , Abu‐AishaH , et al. Praziquantel, oxamniquine, and metrifonate in the treatment of schistosomiasis in Riyadh. Annals of Saudi Medicine1990;10(3):296‐8. ">Al Aska 1990 SAU</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saudi Arabia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> </tbody> </table> </div> <section id="CD000528-sec-0113"> <h6 class="title">Parasitological failure</h6> <p>We did not identify statistically significant differences between oxamniquine (at doses from 10 mg/kg to 60 mg/kg) and praziquantel 40 mg/kg at one month (see <a href="./references#CD000528-fig-0058" title="">Analysis 13.1</a>). No difference was demonstrable at three months between 25 to 30 mg/kg (three trials, 319 participants), 40 mg/kg (one trial, 18 participants) or 50 to 60 mg/kg (one trial, 14 participants, <a href="./references#CD000528-fig-0059" title="">Analysis 13.2</a>). However, 10 to 20 mg/kg of oxamniquine did result in significantly more failures (RR 3.42, 95% CI 1.10 to 10.61, two trials, 135 participants, <a href="./references#CD000528-fig-0059" title="">Analysis 13.2</a>). </p> <p>In addition, there were no differences between oxamniquine (lower or higher dose) and praziquantel (40 mg/kg) at six months (nine trials, 1167 participants, <a href="./references#CD000528-fig-0060" title="">Analysis 13.3</a>) or 12 months (one trial, 52 participants, <a href="./references#CD000528-fig-0061" title="">Analysis 13.4</a>). </p> </section> <section id="CD000528-sec-0114"> <h6 class="title">Egg reduction</h6> <p>Three trials from Brazil, Ethiopia and Malawi compared oxamniquine 15, 20, 30, 40, and 50 mg/kg with praziquantel 40 mg/kg and measured high percent egg reduction at one month (82.9% to 100% for oxamniquine versus 90% to 92.8% for praziquantel, two trials, 391 participants), three months (70.2% to 99.5% for oxamniquine versus 70% to 100% for praziquantel, three trials, 440 participants), six months (32.5% to 97% for oxamniquine versus 33.6% to 96.8% for praziquantel, three trials, 291 participants), and 12 months (94% for oxamniquine versus 96% for praziquantel, one trial, 91 participants, <a href="./references#CD000528-fig-0062" title="">Analysis 13.5</a>). </p> </section> <section id="CD000528-sec-0115"> <h6 class="title">Adverse events</h6> <p>In five trials reporting from Brazil, Ethiopia, Malawi, Saudi Arabia and Tanzania that assessed adverse events, only two serious adverse events were recorded (both with oxamniquine) in two trials: one from a moderate endemicity setting in Ethiopia that used 30 mg/kg in a split dose given the same day; and one trial from Saudi Arabia that used a single dose of 25 mg/kg. No further differences were observed in the number and type of adverse events between oxamniquine and praziquantel although dizziness was recorded in excess with oxamniquine and abdominal pain with praziquantel (<a href="#CD000528-tbl-0015">Table 11</a>). </p> <div class="table" id="CD000528-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events: different oxamniquine dose versus praziquantel (40 mg/kg)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0002" title="Al‐AskaAK , Al‐MoflehIA , Al‐RashedR , HafezMA , Al‐NozhaM , Abu‐AishaH , et al. Praziquantel, oxamniquine, and metrifonate in the treatment of schistosomiasis in Riyadh. Annals of Saudi Medicine1990;10(3):296‐8. ">Al Aska 1990 SAU</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (25 mg/kg) single dose</p> <p>Praziquantel (40 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One serious adverse event (seizure) was recorded in the oxamniquine 25 mg/kg group. Transient dizziness, abdominal pain and nausea were most commonly reported (oxamniquine first): </p> <p>Dizziness: 36% versus 20%</p> <p>Abdominal pain: 25% versus 12%</p> <p>Nausea: 10% versus 8 %</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0007" title="BranchiniML , PedroR J de , DiasLC , DeberaldiniER . Double‐blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):315‐21. ">Branchini 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (14 mg/kg) single dose</p> <p>Praziquantel (45 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were recorded. Adverse events were minor and transient. Dizziness, abdominal pain and nausea were most frequently reported (oxamniquine first): </p> <p>Dizziness: 44.2% versus 46.9%</p> <p>Abdominal pain: 3.8% versus 24.5%</p> <p>Nausea: 5.8% versus 8.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0044" title="RugemalilaJB , AsilaJ , ChimbeA . Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. Journal of Tropical Medicine and Hygiene1984;87(6):231‐5. ">Rugemalila 1984 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (15 mg/kg) single dose</p> <p>Praziquantel (40 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were recorded. Transient abdominal pain and drowsiness were commonly reported (oxamniquine first): </p> <p>Abdominal pain: 16% versus 63%</p> <p>Drowsiness: 25% versus 11%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0048" title="TaddeseK , ZeinZA . Comparison between the efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infections on a sugar estate in Ethiopia. Annals of Tropical Medicine and Parasitology1988;82(2):175‐80. ">Taddese 1988 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (15 mg/kg) single dose</p> <p>Oxamniquine 30 mg/kg :15 mg/kg twice in one day</p> <p>Praziquantel (40 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One serious adverse event (seizure) was recorded with oxamniquine 30 mg/kg. Adverse events were minor and transient. Dizziness and abdominal pain were commonly reported (oxamniquine lower dose first): </p> <p>Dizziness: 22%, 16% versus 20%</p> <p>Abdominal pain: 20%, 28% versus 24%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0050" title="TeesdaleCH , ChitsuloL , PughRN . Oxamniquine dosage in Malawi. East African Medical Journal1984;61(1):40‐4. ">Teesdale 1984 MWI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (30 mg/kg) single dose</p> <p>Oxamniquine (40 mg/kg) single dose</p> <p>Oxamniquine (50 mg/kg): 25 mg/kg twice in one day</p> <p>Praziquantel (40 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were recorded. Transient dizziness was commonly reported among participants receiving oxamniquine. There was no difference in events between oxamniquine 30, 40 and 50 mg/kg (oxamniquine lower dose first): </p> <p>Dizziness: 30.8%, 29.2%, 30.8% versus 8.3%</p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0116"> <h5 class="title">Analysis 14: Myrrh (Mirazid) versus praziquantel</h5> <section id="CD000528-sec-0117"> <h6 class="title">Parasitological failure</h6> <p>Myrhh (Mirazid) was tested in two trials at a single daily dose of 300 mg for three days, and almost all failed treatment at three to six weeks (RR 4.08, 95% CI 2.87 to 5.78, 236 participants, <a href="./references#CD000528-fig-0063" title="">Analysis 14.1</a>). Consequently, further investigation of this compound was abandoned. </p> </section> <section id="CD000528-sec-0118"> <h6 class="title">Egg reduction rate</h6> <p>There were only small reductions in reported percent geometric mean egg reduction in these two studies, but they were not clinically important (<a href="./references#CD000528-fig-0064" title="">Analysis 14.2</a>). </p> </section> <section id="CD000528-sec-0119"> <h6 class="title">Adverse events</h6> <p>No trial reports adverse events.</p> </section> </section> </section> <section id="CD000528-sec-0120"> <h4 class="title">Section 2. Combination therapies</h4> <section id="CD000528-sec-0121"> <h5 class="title">Analysis 15: Praziquantel plus artesunate versus praziquantel alone</h5> <p>One trial conducted from 1999 to 2000 in a high endemicity setting in Senegal evaluated artesunate plus praziquantel versus praziquantel alone. </p> <section id="CD000528-sec-0122"> <h6 class="title">Parasitological failure</h6> <p>In this setting, parasitological failure at one month occurred in 50% of participants given praziquantel 40 mg/kg alone. The addition of artesunate 12 mg/kg given in a divided dose of 2.5 mg/kg daily for five days resulted in a lower failure rate at one month but this did not reach statistical significance (one trial, 75 participants, <a href="./references#CD000528-fig-0065" title="">Analysis 15.1</a>). At three and six months no additional benefit with artesunate plus praziquantel was seen. </p> </section> <section id="CD000528-sec-0123"> <h6 class="title">Egg reduction</h6> <p>Geometric mean egg reductions appear lower with combination treatment but tests of statistical significance were not reported, and the clinical relevance of this finding are unclear (one trial, 75 participants, <a href="./references#CD000528-fig-0068" title="">Analysis 15.4</a>). </p> </section> <section id="CD000528-sec-0124"> <h6 class="title">Adverse events</h6> <p>Adverse events were not reported.</p> </section> </section> <section id="CD000528-sec-0125"> <h5 class="title">Analysis 16: Praziquantel plus oxamniquine versus praziquantel alone</h5> <p>Only one trial in a high endemicity setting in Brazil published in 1987 has evaluated oxamniquine plus praziquantel versus praziquantel alone. </p> <section id="CD000528-sec-0126"> <h6 class="title">Parasitological failure</h6> <p>Compared to praziquantel alone (40 mg/kg in two divided doses on one day), a combination of oxamniquine (7.5 mg/kg) plus praziquantel (20 mg/kg) did not demonstrate any statistically significant benefits at three, six or 12 months follow‐up (one trial, 52 participants, <a href="./references#CD000528-fig-0069" title="">Analysis 16.1</a>). </p> </section> <section id="CD000528-sec-0127"> <h6 class="title">Egg reduction</h6> <p>The combination treatment was associated with lower geometric mean egg reductions at three, six and 12 months but tests of statistical significance were not reported (one trial, 52 participants, <a href="./references#CD000528-fig-0072" title="">Analysis 16.4</a>). </p> </section> <section id="CD000528-sec-0128"> <h6 class="title">Adverse events</h6> <p>These were not reported.</p> </section> </section> <section id="CD000528-sec-0129"> <h5 class="title">Analysis 17: Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg) </h5> <p>One small trial of schoolchildren from a high endemicity setting co‐endemic for <i>S. mansoni</i> and <i>S. haematobium</i> in Zimbabwe investigated different oxamniquine and praziquantel dose combinations. </p> <section id="CD000528-sec-0130"> <h6 class="title">Parasitological failure</h6> <p>Children aged seven to 16 years and excreting more than 100 eggs per gram of stool were included in this trial. Statistically fewer failures were seen with the higher dose‐combination at one month (RR 6.30, 95% CI 1.60 to 24.75, one trial, 28 participants, <a href="./references#CD000528-fig-0073" title="">Analysis 17.1</a>), but not at three months (one trial, 29 participants, <a href="./references#CD000528-fig-0074" title="">Analysis 17.2</a>) or six months (one trial, 20 participants, <a href="./references#CD000528-fig-0075" title="">Analysis 17.3</a>). </p> </section> <section id="CD000528-sec-0131"> <h6 class="title">Egg reduction</h6> <p>The percentage egg reduction also appeared to be lower in those receiving the higher dose combination but tests of statistical significance were not reported (one trial, 59 participants, <a href="./references#CD000528-fig-0076" title="">Analysis 17.4</a>). </p> </section> <section id="CD000528-sec-0132"> <h6 class="title">Adverse events</h6> <p>No serious adverse events were recorded and the incidence of non‐severe events did not differ between combinations. About 70% of children reported abdominal discomfort but these were transient and had resolved by the following day (<a href="#CD000528-tbl-0016">Table 12</a>). </p> <div class="table" id="CD000528-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse events: oxamniquine plus praziquantel versus oxamniquine plus praziquantel</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0008" title="CreaseyAM , TaylorP , ThomasJE . Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean schoolchildren. Central African Journal of Medicine1986;32(7):165‐7. ">Creasey 1986 ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (4 mg/kg) plus praziquantel (8 mg/kg) versus oxamniquine (10 mg/kg) plus praziquantel (20 mg/kg) </p> <p>Oxamniquine (7.5 mg/kg) plus</p> <p>praziquantel (15 mg/kg) versus</p> <p>praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Adverse events were minor and did not differ between combinations. One child reported dizziness five minutes after treatment but required no further treatment and was well the following day. About 70% of children reported abdominal discomfort but these were transient and had resolved the following day. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD000528-sec-0133"> <h5 class="title">Analysis 18: Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg) </h5> <p>One trial in Zimbabwe investigated slightly higher oxamniquine and praziquantel dose combinations. The included children had to excrete more than 100 eggs per gram of stool. </p> <section id="CD000528-sec-0134"> <h6 class="title">Parasitological failure</h6> <p>A statistically significant difference was not demonstrated at one, three and six months (one trial, 48 participants, <a href="./references#CD000528-fig-0077" title="">Analysis 18.1</a>, <a href="./references#CD000528-fig-0078" title="">Analysis 18.2</a>, <a href="./references#CD000528-fig-0079" title="">Analysis 18.3</a>). </p> </section> <section id="CD000528-sec-0135"> <h6 class="title">Egg reduction rate</h6> <p>Percent egg reductions were high at one, three and six months (82% to 96.1% versus 66.3% to 96.6%, one trial, 59 participants, <a href="./references#CD000528-fig-0080" title="">Analysis 18.4</a>). </p> </section> <section id="CD000528-sec-0136"> <h6 class="title">Adverse events</h6> <p>No serious adverse events were recorded apart from one child who reported dizziness immediately after treatment but required no further treatment (<a href="#CD000528-tbl-0016">Table 12</a>). </p> </section> </section> </section> <section id="CD000528-sec-0137"> <h4 class="title">Section 3. Do failure rates vary in children and adults?</h4> <section id="CD000528-sec-0138"> <h5 class="title">Praziquantel</h5> <p>A subgroup analysis conducted in two studies from Burundi raised concern that parasitological failure following 40 mg/kg may be higher in children than in adults. The frequency of parasitological treatment failure was consistently higher in children than adults at one, three, six, and 12 months, and this was also observed for doses of 20 mg/kg and 30 mg/kg (see <a href="#CD000528-tbl-0017">Table 13</a>). </p> <div class="table" id="CD000528-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Non‐randomized exploratory analysis of age (praziquantel)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Dose (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Time point (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Number failed/number examined  (%) <sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Children (&lt;20 years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adults (≥20 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48/109 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/61 (43)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49/100 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/54 (30)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/109 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/58 (33)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60/101 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/59 (36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/93 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/48 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/104 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/65 (18)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/91 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/40 (10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/98 (38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/66 (15)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/94 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/46 (13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/94 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/61 (31)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/91 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/44 (20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73/92 (79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/51 (37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/94 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/42 (12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/81 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/54 (4)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/87 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/32 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/83 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/54 (20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/92 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/37 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/76 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/51 (20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/84 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/38 (26)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Number failed/number examined (%) presented for the praziquantel treatment group of each study that presents data for adults and children separately. </p> </div> </div> </section> <section id="CD000528-sec-0139"> <h5 class="title">Oxamniquine</h5> <p>Similarly, a subgroup analysis of two studies from Burundi and Sudan administering oxamniquine has shown a consistent pattern of higher parasitological treatment failure in children than adults at one to 12 months (see <a href="#CD000528-tbl-0018">Table 14</a>). </p> <div class="table" id="CD000528-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Non‐randomized exploratory analysis of age (oxamniquine)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Dose (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Time point (month)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Number failed/number examined (%) <sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Children (&lt; 20 years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adults (≥ 20 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/41 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/55 (6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/57 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/95 (17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 6/41 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/55 (7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/56 (54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/102 (22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/41 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/55 (16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/49 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/86 (23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/41 (93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/83 (24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/42 (38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/76 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/46 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/77 (10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/41 (54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/62 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/39 (62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/67 (15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/43 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/57 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/49 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/67 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/57 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/51 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/65 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/31 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/57 (9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/42 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/62 (18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/38 (66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/60 (18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/42 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/58 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/42 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/58 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/42 (38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/58 (2)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Number failed/number examined (%) presented for the oxamniquine treatment group of each study that presents data for adults and children separately. </p> </div> </div> <p>Subgroup analysis of treatment arms receiving 40 mg/kg in the other included studies was not possible given the available data. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000528-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000528-sec-0140"></div> <section id="CD000528-sec-0141"> <h3 class="title" id="CD000528-sec-0141">Summary of main results</h3> <p>Compared to placebo, praziquantel 40 mg/kg substantially reduced parasitological treatment failure at one month post‐treatment (<i>moderate quality evidence</i> ). Compared to this standard dose, lower doses of 20 mg/kg and 30 mg/kg were inferior (<i>low quality evidence</i> ); and higher doses, up to 60 mg/kg, have not shown any advantage (<i>moderate quality evidence</i>). </p> <p>Compared to placebo, oxamniquine 40 mg/kg substantially reduced parasitological treatment failure at three months (<i>moderate quality evidence</i> ). Lower doses than 40 mg/kg were inferior at one month (<i>low quality evidence</i> ), and higher doses such as 60 mg/kg have not shown a consistent benefit (<i>low quality evidence</i>). </p> <p>Ten trials compared oxamniquine at 20, 30 and 60 mg/kg with praziquantel 40 mg/kg and did not show any convincing differences in failure rate and percent egg reduction. Only one small study directly compared praziquantel 40 mg/kg with oxamniquine 40 mg/kg and did not demonstrate a statistically significant difference in parasitological failure (<i>very low quality evidence</i>). </p> <p>Combining praziquantel with artesunate has not been shown to have benefits in terms of failure rate compared to praziquantel alone at one month, three or six months (one trial, 75 participants, <i>very low quality evidence</i>). Two trials have also compared combinations of praziquantel and oxamniquine in different doses but did not find statistically significant differences in failure rate. </p> <p>Compared to 40 mg/kg, no dose effect was demonstrable for clinical improvement with lower doses (20 and 30 mg/kg) of praziquantel or oxamniquine in resolving abdominal pain, diarrhoea, blood in stool, hepatomegaly, and splenomegaly at one, three, six, and 12 months, or up to two years of follow‐up. Adverse events were not well reported but were mostly described as minor and transient. </p> </section> <section id="CD000528-sec-0142"> <h3 class="title" id="CD000528-sec-0142">Overall completeness and applicability of evidence</h3> <p>For praziquantel, the evidence presented is generally supportive of the current WHO recommended dose of 40 mg/kg to treat <i>S. mansoni</i> infection (<a href="./references#CD000528-bbs2-0163" title="WHO . Prevention and control of schistosomiasis and soil‐transmitted helminthiasis. Report of a WHO expert committee WHO Technical Report Series. No 912.1‐57. 2002. ">WHO 2002</a>). Parasitological cure as low as 57% has been reported in Kenya in the 1990s (<a href="./references#CD000528-bbs2-0036" title="OldsGR , KingCH , HewlettJ , OlvedaR , WuG , OumaJ , et al. Double‐blind placebo‐controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. Journal of Infectious Diseases1999;179(4):996‐1003. ">Olds 1999 KEN</a>), and 52% in Senegal in 1993 (<a href="./references#CD000528-bbs2-0023" title="GuisseF , PolmanK , StelmaFF , MbayeA , TallaI , NiangM , et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. American Journal of Tropical Medicine and Hygiene1997;56(5):511‐4. ">Guisse 1997 SEN</a>). However, higher efficacy has been seen in more recent trials; Tanzania (81%), Mauritania (95%) and Brazil (92%) in 2006/2007 (<a href="./references#CD000528-bbs2-0037" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 BRA</a>; <a href="./references#CD000528-bbs2-0038" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 MRT</a>; <a href="./references#CD000528-bbs2-0039" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 TZA</a>), and Uganda (87%) in 2003/2005 (<a href="./references#CD000528-bbs2-0051" title="TweyongyereR , MawaPA , EmojongNO , MpairweH , JonesFM , DuongT , et al. Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo‐controlled trial. BMC Infectious Diseases2009;9:32. TweyongyereR , MawaPA , Ngom‐WegiS , NdibazzaJ , DuongT , VennervaldBJ , et al. Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo‐controlled trial. Journal of Infectious Diseases2008;198(12):1870‐9. ">Tweyongyere 2009 UGA</a>). The lower cure rates from the earlier studies could be expected from the high endemicities where pre‐treatment intensity of infection were very high (prevalence &gt; 80%) compared to the recent studies (prevalence &lt; 30%). In such situations, even at 95% efficacy, a sufficient number of surviving schistosomes would remain, causing sustained egg excretion in most of the treated participants (<a href="./references#CD000528-bbs2-0093" title="Danso‐AppiahA , DeVlasSJ . Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends in Parasitology2002;18(3):125‐9. ">Danso‐Appiah 2002</a>). Furthermore, as a result of intense transmission, most treated participants might have acquired large numbers of new infections just before treatment and as immature worms are less sensitive to praziquantel most would have escaped drug action and developed into egg‐laying adult worms shortly after treatment to present as failures. The high diagnostic sensitivity (mostly duplicate slides from two or more consecutive stool specimens) and lower dose of praziquantel applied in the earlier studies (except <a href="./references#CD000528-bbs2-0023" title="GuisseF , PolmanK , StelmaFF , MbayeA , TallaI , NiangM , et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. American Journal of Tropical Medicine and Hygiene1997;56(5):511‐4. ">Guisse 1997 SEN</a>) would have also contributed to the observed lower cure rates. </p> <p>The results in this review appear to be generalizable elsewhere but it should be noted that these trials excluded preschool children under five years and concerns remain that this dose may be less effective in this group. This is because praziquantel works in synergy with host immune status (<a href="./references#CD000528-bbs2-0145" title="SabahAA , FletcherC , WebbeG , DoenhoffMJ . Schistosoma mansoni: chemotherapy of infections of different ages. Experimental Parasitology1986;61:294‐303. ">Sabah 1986</a>) and this is not yet fully developed in very young children. A subgroup analysis conducted in two studies from Burundi with praziquantel at 40 mg/kg and another two studies from Burundi and Sudan with oxamniquine 40 mg/kg raises concern as parasitological failure was consistently higher in children than in adults at one to 12 months of follow‐up. This trend was also observed for doses of 20 mg/kg and 30 mg/kg for both treatments, and a higher dose (60 mg/kg) for oxamniquine. </p> <p>Higher doses than 40 mg/kg have been national policy in Brazil since 1995: 60 mg/kg for children and 50 mg/kg for adolescents and adults. We found little direct evidence from randomized controlled trials to support or refute this as a policy. Only a single trial from Brazil reported outcomes at one month and this failed to show a statistically significant advantage with 60 mg/kg compared to 40 mg/kg, and excluded children aged less than 10 years (<a href="./references#CD000528-bbs2-0037" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 BRA</a>). Several further trials from Brazil have evaluated higher doses and longer regimens but these only reported outcomes at six months or beyond. These do offer some limited evidence that increasing the dose of praziquantel might have parasitological benefits. </p> <p>There is no justification for using lower doses, even if potentially effective in morbidity control, as sub‐curative doses may eventually select for drug resistant parasites (<a href="./references#CD000528-bbs2-0102" title="DoenhoffMJ . Is schistosomacidal chemotherapy sub‐curative? Implications for drug resistance. Parasitology Today1998;14:434‐5. ">Doenhoff 1998</a>; <a href="./references#CD000528-bbs2-0104" title="DoenhoffMJ , CioliD , UtzingerJ . Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Current Opinion in Infectious Diseases2008;21(6):659‐67. ">Doenhoff 2008</a>). </p> <p>Praziquantel is known to be less effective on immature schistosomes than adult worms (<a href="./references#CD000528-bbs2-0145" title="SabahAA , FletcherC , WebbeG , DoenhoffMJ . Schistosoma mansoni: chemotherapy of infections of different ages. Experimental Parasitology1986;61:294‐303. ">Sabah 1986</a>), and combination therapy (with drugs with unrelated mechanisms of action and targeting the different developmental stages of the schistosomes), has potential as a future control strategy. Potential partner drugs include oxamniquine and the artemisinin derivatives. Of these, the artemisinin derivatives have been shown to be effective against immature schistosomes in laboratory studies (<a href="./references#CD000528-bbs2-0153" title="UtzingerJ , XiaoS , NGoranEK , BergquistR , TannerM . The potential of artemether for the control of schistosomiasis. International Journal for Parasitology2001;31(14):1549‐62. ">Utzinger 2001</a>; <a href="./references#CD000528-bbs2-0155" title="UtzingerJ , CholletJ , TuZ , XiaoS , TannerM . Comparative study of the effects of artemether and artesunate on juvenile and adult Schistosoma mansoni in experimentally infected mice. Transactions of the Royal Society of Tropical Medicine Hygiene2002;96(3):318–23. ">Utzinger 2002</a>; <a href="./references#CD000528-bbs2-0156" title="UtzingerJ , KeiserJ , XiaoSH , TannerM , SingerBH . Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrobial Agents and Chemotherapy2003;47:1487‐95. ">Utzinger 2003</a>; <a href="./references#CD000528-bbs2-0157" title="UtzingerJ , XiaoSH , TannerM , KeiserJ . Artemisinins for schistosomiasis and beyond. Current Opinion on Investigational Drugs2007;8(2):105‐16. ">Utzinger 2007</a>), and there is some indirect evidence for efficacy from non‐randomized studies in urinary schistosomiasis (<a href="./references#CD000528-bbs2-0098" title="DeClercqD , VercruysseJ , KongsA , VerleP , DompnierJP , FayePC . Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. Acta Tropica2002;82:61‐6. ">De Clercq 2002</a>; <a href="./references#CD000528-bbs2-0124" title="Inyang‐EtohPC , EjezieGC , UsehMF , Inyang‐EtohEC . Efficacy of artesunate in the treatment of urinary schistosomiasis, in an endemic community in Nigeria. Annals of Tropical Medicine and Parasitology2004;98(5):491‐9. ">Inyang‐Etoh 2004</a>; <a href="./references#CD000528-bbs2-0086" title="BoulangerD , DiengY , CisseB , RemoueF , CapuanoF , DiemeJL , et al. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(2):113‐6. ">Boulanger 2007</a>; <a href="./references#CD000528-bbs2-0125" title="Inyang‐EtohPC , EjezieGC , UsehMF , Inyang‐EtohEC . Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. Transactions of the Royal Society of Tropical Medicine and Hygiene2009;103:38‐44. ">Inyang‐Etoh 2009</a>), and from people with malaria co‐infected <i>S. haematobium</i> (<a href="./references#CD000528-bbs2-0086" title="BoulangerD , DiengY , CisseB , RemoueF , CapuanoF , DiemeJL , et al. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Transactions of the Royal Society of Tropical Medicine and Hygiene2007;101(2):113‐6. ">Boulanger 2007</a>). However, to date only a single trial has directly evaluated praziquantel plus artesunate and no additional benefit was observed compared to praziquantel alone (<a href="./references#CD000528-bbs2-0016" title="DeClercqD , VercruysseJ , VerleP , KongsA , DiopM . What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections?. Tropical Medicine and International Health2000;5(10):744‐6. ">De Clercq 2000 SEN</a>). </p> <p>For oxamniquine, there is no current consensus on the optimal dosing regimen and it has largely fallen out of use in favour of praziquantel. Although the presented data are now more than 20 years old, and suffers some methodological problems, there is sufficient evidence of its efficacy against <i>S. mansoni</i> to suggest that it could be reinstated as an alternate treatment to decrease the pressure on praziquantel. However, a limitation of oxamniquine is that its effect is restricted to <i>S. mansoni</i> as this is the only species possessing the enzyme which converts oxamniquine to its active metabolite (<a href="./references#CD000528-bbs2-0090" title="CioliD , Pica‐MattocciaL , ArcherS . Antischistosomal drugs: past, present ... and future?. Pharmacology and Therapeutics1995;68(1):35‐85. ">Cioli 1995</a>). It is therefore unsuitable for use in areas where co‐infection with <i>S. haematobium</i> is common. </p> <p>The optimal dose of oxamniquine may also be 40 mg/kg but further studies are required to confirm this, preferably in direct comparison with praziquantel, and trials should include and evaluate the efficacy of this dose in young children. </p> <p>Safety was under reported and inconsistently assessed in most of these clinical trials. Furthermore, only the few studies comparing the intervention versus placebo allow identification of potentially drug‐related events. From these few studies it is therefore not possible to provide a reliable account of treatment tolerability. </p> </section> <section id="CD000528-sec-0143"> <h3 class="title" id="CD000528-sec-0143">Quality of the evidence</h3> <p>The quality of evidence was assessed using the GRADE methodology and displayed in summary of findings (SOF) tables for the main comparisons. The level of quality is judged on a 4‐point scale. High quality evidence implies that level of confidence in the effect estimate is high and that further research is unnecessary. Moderate quality evidence implies lower confidence in the result and further research may have an important impact on the result. Low and very low quality evidence reflect increasing uncertainty in the result and a greater need for further research. </p> <p>The evidence presented is generally considered to be of moderate or low quality due to concerns related to three key factors: i) the age of the trials, with the majority more than 20 years old, ii) the poor methodological reporting of many of these older trials, and iii) the number and size of the trials being small and often underpowered to reliably detect statistically significant differences. The specific reasons for downgrading the quality of the evidence are given in the footnotes to the SOF tables. </p> </section> <section id="CD000528-sec-0144"> <h3 class="title" id="CD000528-sec-0144">Potential biases in the review process</h3> <p>A few minor difficulties in extracting the data from the available papers should be noted but these are unlikely to have introduced major bias into this review. For three trials (<a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a>; <a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a>; <a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a>), data on parasitological failure were obtained from figures and might not be the exact estimates. One trial (<a href="./references#CD000528-bbs2-0047" title="SukwaTY . A community‐based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. Annals of Tropical Medicine and Parasitology1993;87(2):185‐94. ">Sukwa 1993 ZMB</a>) actually reported reinfection rate but this is included in this review because this outcome is similar to failure rate. The trial by <a href="./references#CD000528-bbs2-0051" title="TweyongyereR , MawaPA , EmojongNO , MpairweH , JonesFM , DuongT , et al. Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo‐controlled trial. BMC Infectious Diseases2009;9:32. TweyongyereR , MawaPA , Ngom‐WegiS , NdibazzaJ , DuongT , VennervaldBJ , et al. Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo‐controlled trial. Journal of Infectious Diseases2008;198(12):1870‐9. ">Tweyongyere 2009 UGA</a> was a nested cohort study within a larger mother and baby cohort study in which pregnant women found to be infected with <i>S. mansoni</i> were randomized to receive praziquantel or placebo. Despite representing a special population, this is not likely to affect the validity of the results. </p> </section> <section id="CD000528-sec-0145"> <h3 class="title" id="CD000528-sec-0145">Agreements and disagreements with other studies or reviews</h3> <p>A non‐Cochrane review compared praziquantel with placebo in two studies in Brazil and showed slightly higher cure rate with praziquantel (<a href="./references#CD000528-bbs2-0137" title="LiuR , DongHF , GuoY , ZhaoQP , JiangMS . Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta‐analysis. Parasites and Vectors2011;4:201. ">Liu 2011</a>). The reliability of the evidence in this review cannot be established given that the two studies that assessed this outcome involved only 25 participants. </p> <p>The effects of praziquantel and artesunate in urinary schistosomiasis due to <i>S. haematobium</i> have been evaluated in a separate Cochrane review last published in 2008. Praziquantel was found to be effective against <i>S. haematobium</i> with few adverse events, and similarly to this review there was insufficient evidence for the use of artesunate monotherapy or combination therapy (<a href="./references#CD000528-bbs2-0095" title="Danso‐AppiahA , UtzingerJ , LiuJ , OlliaroPL . Drugs for treating urinary schistosomiasis. Cochrane Database of Systematic Reviews2008, Issue Issue 3. Art. No: CD000053. DOI: 10.1002/14651858.CD000053.pub2. ">Danso‐Appiah 2008</a>). </p> <p>Limitations in the design and methodology in schistosomiasis trials identified during the earlier Cochrane review, and consequent future research needs have also been reported elsewhere (<a href="./references#CD000528-bbs2-0096" title="Danso‐AppiahA , GarnerP , OlliaroPL , UtzingerJ . Treatment of urinary schistosomiasis: methodological issues and research needs identified through a Cochrane systematic review. Parasitology2009;136(13):1837‐49. ">Danso‐Appiah 2009</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000528-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000528-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000528-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Praziquantel versus placebo, Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Praziquantel versus placebo, Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Praziquantel versus placebo, Outcome 2 Parasitological failure at six months." data-id="CD000528-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Praziquantel versus placebo, Outcome 2 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Praziquantel versus placebo, Outcome 3 Parasitological failure at 12 months." data-id="CD000528-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Praziquantel versus placebo, Outcome 3 Parasitological failure at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Praziquantel (lower dose) versus praziquantel 40 mg/kg, Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Praziquantel (lower dose) versus praziquantel 40 mg/kg, Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Praziquantel (lower dose) versus praziquantel 40 mg/kg, Outcome 2 Parasitological failure at three months." data-id="CD000528-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Praziquantel (lower dose) versus praziquantel 40 mg/kg, Outcome 2 Parasitological failure at three months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Praziquantel (lower dose) versus praziquantel 40 mg/kg, Outcome 3 Parasitological failure at six to 12 months." data-id="CD000528-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Praziquantel (lower dose) versus praziquantel 40 mg/kg, Outcome 3 Parasitological failure at six to 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0009"> <p> <div class="table" id="CD000528-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Geometric mean % egg reduction at 6 months 30 mg/kg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Geometric mean % egg reduction at 6 months 40 mg/kg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Katz 1981 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Praziquantel (lower dose) versus praziquantel 40 mg/kg, Outcome 4 Percent egg reduction. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0009">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 1 Resolution of abdominal pain: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 1 Resolution of abdominal pain: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 2 Resolution of abdominal pain: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 2 Resolution of abdominal pain: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 3 Resolution of diarrhoea: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 3 Resolution of diarrhoea: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 4 Resolution of diarrhoea: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 4 Resolution of diarrhoea: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 5 Resolution of blood in stool: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 5 Resolution of blood in stool: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 6 Resolution of blood in stool: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 6 Resolution of blood in stool: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 7 Resolution of hepatomegaly: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 7 Resolution of hepatomegaly: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 8 Resolution of hepatomegaly: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 8 Resolution of hepatomegaly: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 9 Resolution of splenomegaly: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 9 Resolution of splenomegaly: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 10 Resolution of splenomegaly: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg, Outcome 10 Resolution of splenomegaly: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Praziquantel (higher dose) versus praziquantel 40 mg/kg, Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Praziquantel (higher dose) versus praziquantel 40 mg/kg, Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Praziquantel (higher dose) versus praziquantel 40 mg/kg, Outcome 2 Parasitological failure at six months." data-id="CD000528-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Praziquantel (higher dose) versus praziquantel 40 mg/kg, Outcome 2 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Praziquantel (higher dose) versus praziquantel 40 mg/kg, Outcome 3 Parasitological failure at six to 12 months." data-id="CD000528-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Praziquantel (higher dose) versus praziquantel 40 mg/kg, Outcome 3 Parasitological failure at six to 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0023"> <p> <div class="table" id="CD000528-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Praziquantel (60 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Praziquantel (40 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guisse 1997 SEN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olliaro 2011 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs and those not excreting eggs at follow‐up </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olliaro 2011 MRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean EPG of participants excreting eggs and those not excreting eggs at follow‐up </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olliaro 2011 TZA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs and those not excreting eggs at follow‐up </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Praziquantel (higher dose) versus praziquantel 40 mg/kg, Outcome 4 Percent egg reduction at one month. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose, Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose, Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose, Outcome 2 Parasitological failure at three months." data-id="CD000528-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose, Outcome 2 Parasitological failure at three months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose, Outcome 3 Parasitological failure at six months." data-id="CD000528-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose, Outcome 3 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0027"> <p> <div class="table" id="CD000528-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Praziquantel (40 mg/kg) in a divided dose of 20 mg/kg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Praziquantel (40 mg/kg) single dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kardaman 1983 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &gt; 0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose, Outcome 4 Percent egg reduction at one month. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0027">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Praziquantel alternative dosing (Brazil), Outcome 1 Parasitological failure at six months." data-id="CD000528-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Praziquantel alternative dosing (Brazil), Outcome 1 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0029"> <p> <div class="table" id="CD000528-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Geometric mean % egg reduction at 6 months 30 mg/kg x 2 daily for 2 days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Geometric mean % egg reduction at 6 months 30 mg/kg x 2 in one day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>p‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>da Cunha 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants with viable eggs found in rectal mucosa biopsies</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Praziquantel alternative dosing (Brazil), Outcome 2 Percent egg reduction at six months. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0029">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0030"> <p> <div class="table" id="CD000528-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Geometric mean % egg reduction 30 mg/kg x 2 daily for 3 days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Geometric mean % egg reduction 30 mg/kg x 2 in one day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>p‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>da Cunha 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants with viable eggs found in rectal mucosa biopsies</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Praziquantel alternative dosing (Brazil), Outcome 3 Percent egg reduction at six months. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0030">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0031"> <p> <div class="table" id="CD000528-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Geometric mean % egg reduction 30 mg/kg daily for 6 days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Geometric mean % egg reduction 30 mg/kg x 2 in one day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>p‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>da Cunha 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants with viable eggs found in rectal mucosa biopsies</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Praziquantel alternative dosing (Brazil), Outcome 4 Percent egg reduction at six months. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0031">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oxamniquine versus placebo, Outcome 1 Parasitological failure at three to four months." data-id="CD000528-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Oxamniquine versus placebo, Outcome 1 Parasitological failure at three to four months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oxamniquine versus placebo, Outcome 2 Parasitological failure at six to 10 months." data-id="CD000528-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Oxamniquine versus placebo, Outcome 2 Parasitological failure at six to 10 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0034"> <p> <div class="table" id="CD000528-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>p‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Oxamniquine (40 mg/kg) versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1984 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean EPG based on participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1986 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.6% increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean EPG based on participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Oxamniquine (20 to 30 mg/kg) versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1984 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean EPG based on participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1986 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.6% increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean EPG based on participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Oxamniquine (60 mg/kg) versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1984 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59% increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean EPG based on participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1986 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.6% increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Geometric mean EPG based on participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Oxamniquine versus placebo, Outcome 3 Percent egg reduction at three to four months. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0034">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 2 Parasitological failure at three to four months." data-id="CD000528-fig-0036" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 2 Parasitological failure at three to four months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 3 Parasitological failure at six months." data-id="CD000528-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 3 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 4 Parasitological failure at 12 months." data-id="CD000528-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 4 Parasitological failure at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0039"> <p> <div class="table" id="CD000528-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (lower dose)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (40 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>One month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdel Rahim 1988 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference with H‐ and Wilcoxon‐tests</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1984 ZMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Three to four months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdel Rahim 1988 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant with H‐ and Wilcoxon‐ tests</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1984 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1986 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1984 ZMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Six months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdel Rahim 1988 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1984 ZMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omer 1978 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Oxamniquine (lower dose) versus oxamniquine 40 mg/kg, Outcome 5 Percent egg reduction. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0039">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 1 Resolution of abdominal pain: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0040" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 1 Resolution of abdominal pain: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 2 Resolution of abdominal pain: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0041" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 2 Resolution of abdominal pain: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 3 Resolution of diarrhoea: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0042" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 3 Resolution of diarrhoea: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 4 Resolution of diarrhoea: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0043" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 4 Resolution of diarrhoea: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 5 Resolution of blood in stool: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0044" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 5 Resolution of blood in stool: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 6 Resolution of blood in stool: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0045" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 6 Resolution of blood in stool: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 7 Resolution of hepatomegaly: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0046" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 7 Resolution of hepatomegaly: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 8 Resolution of hepatomegaly: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0047" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 8 Resolution of hepatomegaly: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 9 Resolution of splenomegaly: 20 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0048" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 9 Resolution of splenomegaly: 20 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-009-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-009-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 10 Resolution of splenomegaly: 30 mg/kg versus 40 mg/kg." data-id="CD000528-fig-0049" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9 Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg, Outcome 10 Resolution of splenomegaly: 30 mg/kg versus 40 mg/kg. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-009-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Oxamniquine (higher dose) versus oxamniquine 40 mg/kg, Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0050" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Oxamniquine (higher dose) versus oxamniquine 40 mg/kg, Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Oxamniquine (higher dose) versus oxamniquine 40 mg/kg, Outcome 2 Parasitological failure at three to four months." data-id="CD000528-fig-0051" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Oxamniquine (higher dose) versus oxamniquine 40 mg/kg, Outcome 2 Parasitological failure at three to four months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Oxamniquine (higher dose) versus oxamniquine 40 mg/kg, Outcome 3 Parasitological failure at six months." data-id="CD000528-fig-0052" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Oxamniquine (higher dose) versus oxamniquine 40 mg/kg, Outcome 3 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0053"> <p> <div class="table" id="CD000528-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (higher dose)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (40 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>One month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdel Rahim 1988 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1984 ZMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibrahim 1980 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Arithmetic Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Three to four months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdel Rahim 1988 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1984 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayele 1986 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1984 ZMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibrahim 1980 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Arithmetic Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Six months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdel Rahim 1988 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gupta 1984 ZMB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported how EPG was calculated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibrahim 1980 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Arithmetic Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omer 1978 SDN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Oxamniquine (higher dose) versus oxamniquine 40 mg/kg, Outcome 4 Percent egg reduction. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0053">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Oxamniquine (lower dose) 15 to 20 mg/kg versus oxamniquine 30 mg/kg, Outcome 1 Parasitological failure." data-id="CD000528-fig-0054" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Oxamniquine (lower dose) 15 to 20 mg/kg versus oxamniquine 30 mg/kg, Outcome 1 Parasitological failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Oxamniquine (higher dose) versus oxamniquine 30 mg/kg, Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0055" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Oxamniquine (higher dose) versus oxamniquine 30 mg/kg, Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Oxamniquine (higher dose) versus oxamniquine 30 mg/kg, Outcome 2 Parasitological failure at three to four months." data-id="CD000528-fig-0056" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Oxamniquine (higher dose) versus oxamniquine 30 mg/kg, Outcome 2 Parasitological failure at three to four months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Oxamniquine (higher dose) versus oxamniquine 30 mg/kg, Outcome 3 Parasitological failure at six months." data-id="CD000528-fig-0057" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Oxamniquine (higher dose) versus oxamniquine 30 mg/kg, Outcome 3 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Oxamniquine versus praziquantel, Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0058" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Oxamniquine versus praziquantel, Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Oxamniquine versus praziquantel, Outcome 2 Parasitological failure at three months." data-id="CD000528-fig-0059" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Oxamniquine versus praziquantel, Outcome 2 Parasitological failure at three months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Oxamniquine versus praziquantel, Outcome 3 Parasitological failure at six months." data-id="CD000528-fig-0060" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Oxamniquine versus praziquantel, Outcome 3 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Oxamniquine versus praziquantel, Outcome 4 Parasitological failure at 12 months." data-id="CD000528-fig-0061" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 Oxamniquine versus praziquantel, Outcome 4 Parasitological failure at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0062"> <p> <div class="table" id="CD000528-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Praziquantel (40 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>One month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taddese 1988 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taddese 1988 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Three months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taddese 1988 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taddese 1988 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported who were involved in EPG calculation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported who were involved in EPG calculation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teesdale 1984 MWI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported who were involved in EPG calculation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zwingenberger 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.1‐67.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Six months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taddese 1988 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants still excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Taddese 1988 ETH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants still excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zwingenberger 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.5‐97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.8‐96.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) of participants still excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>12 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zwingenberger 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) of participants still excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 Oxamniquine versus praziquantel, Outcome 5 Percent egg reduction.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0062">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Myrrh (Mirazid) 300 mg once daily for three days versus praziquantel 40 mg/kg, Outcome 1 Parasitological failure at three to six weeks." data-id="CD000528-fig-0063" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Myrrh (Mirazid) 300 mg once daily for three days versus praziquantel 40 mg/kg, Outcome 1 Parasitological failure at three to six weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0064"> <p> <div class="table" id="CD000528-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Myrrh (Mirazid: 300 mg) daily for 3 days</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Praziquantel (40 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barakat 2005 EGY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Botros 2005 EGY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Myrrh (Mirazid) 300 mg once daily for three days versus praziquantel 40 mg/kg, Outcome 2 Percent egg reduction three to six weeks. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0064">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg), Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0065" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg), Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg), Outcome 2 Parasitological failure at three months." data-id="CD000528-fig-0066" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg), Outcome 2 Parasitological failure at three months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg), Outcome 3 Parasitological failure at six months." data-id="CD000528-fig-0067" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg), Outcome 3 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0068"> <p> <div class="table" id="CD000528-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Artesunate (12 mg/kg) plus Praziquantel (40 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Praziquantel (40 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>One month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>De Clercq 2000 SEN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &gt; 0.2380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) based on participants excreting eggs and those not excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Three months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>De Clercq 2000 SEN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &gt; 0.5552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) based on participants excreting eggs and those not excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Six months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>De Clercq 2000 SEN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P &gt; 0.5892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) based on participants excreting eggs and those not excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15 Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg), Outcome 4 Percent egg reduction. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0068">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg), Outcome 1 Parasitological failure at three months." data-id="CD000528-fig-0069" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg), Outcome 1 Parasitological failure at three months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg), Outcome 2 Parasitological failure at six months." data-id="CD000528-fig-0070" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg), Outcome 2 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-016-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-016-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg), Outcome 3 Parasitological failure at 12 months." data-id="CD000528-fig-0071" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-016-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg), Outcome 3 Parasitological failure at 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-016-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0072"> <p> <div class="table" id="CD000528-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (7.5 mg/kg) plus Praziquantel (20 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Praziquantel (20 mg/kg x 2) in one day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Three months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zwingenberger 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76.9% to 99.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Six months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zwingenberger 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>12 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zwingenberger 1987 BRA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not statistically significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Range) of participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16 Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg), Outcome 4 Percent egg reduction. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0072">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0073" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 2 Parasitological failure at three months." data-id="CD000528-fig-0074" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 2 Parasitological failure at three months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 3 Parasitological failure at six months." data-id="CD000528-fig-0075" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 3 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0076"> <p> <div class="table" id="CD000528-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (4 mg/kg) plus Praziquantel (8 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (10 mg/kg) plus Praziquantel (20 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>One month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Creasey 1986 ZWE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Three months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Creasey 1986 ZWE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Six months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Creasey 1986 ZWE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 4 Percent egg reduction. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0076">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000528-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 1 Parasitological failure at one month." data-id="CD000528-fig-0077" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 1 Parasitological failure at one month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-018-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-018-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 2 Parasitological failure at three months." data-id="CD000528-fig-0078" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-018-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18 Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 2 Parasitological failure at three months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-018-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/urn:x-wiley:14651858:media:CD000528:CD000528-CMP-018-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_t/tCD000528-CMP-018-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 3 Parasitological failure at six months." data-id="CD000528-fig-0079" src="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-018-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18 Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 3 Parasitological failure at six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/media/CDSR/CD000528/image_n/nCD000528-CMP-018-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000528-fig-0080"> <p> <div class="table" id="CD000528-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (7.5 mg/kg) plus Praziquantel (15 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Oxamniquine (10 mg/kg) plus Praziquantel (20 mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P‐value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>One month</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Creasey 1986 ZWE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Three months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Creasey 1986 ZWE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Six months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Creasey 1986 ZWE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EPG (Geometric Mean) of participants excreting eggs at follow‐up</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18 Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg), Outcome 4 Percent egg reduction. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-fig-0080">Navigate to figure in review</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000528-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Praziquantel 40 mg/kg for treating S. mansoni infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Praziquantel 40 mg/kg for treating <i>S. mansoni</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with <i>S. mansoni</i> infection<br/> <b>Settings:</b> Endemic settings<br/> <b>Intervention:</b> Praziquantel 40 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks<sup>1</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Praziquantel 40 mg/kg</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><b>Parasitological failure</b> </p> <p>at 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>69 per 100</b> <br/> (23 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.13</b> <br/> (1.03 to 9.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>414<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2,3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 20 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> <br/> (34 to 72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.23</b> <br/> (1.64 to 3.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>341<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 30 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> <br/> (25 to 44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.52</b> <br/> (1.15 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521<br/> (3 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 60 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21 per 100</b> <br/> (16 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/> (0.73 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>783<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6,7</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus split dose</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> <br/> (3 to 37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.47</b> <br/> (0.13 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>525<br/> (2 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,8</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is given in the footnotes. </p> <p>The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Treatment failure with praziquantel 40 mg/kg ranged from 5% to 48% in the included studies. The risk given here is the median risk in these studies and is given for illustrative purposes.<br/> <sup>2</sup> No serious risk of bias. Both studies adequately concealed allocation and blinded participants and investigators. Loss to follow‐up was high in one study.<br/> <sup>3</sup> No serious inconsistency: Both trials showed statistically significant benefits with praziquantel but the size of the effect varied. In Kenya in 1999 failure with praziquantel was 43% at one month and in Uganda in 2009 it was 18%.<br/> <sup>4</sup> Downgraded by 1 for indirectness: Only two trials from limited settings have evaluated this comparison.<br/> <sup>5</sup> Downgraded by 1 for risk of bias: These trials are more than twenty years old and do not provide an adequate description of methods to reduce the risk of bias.<br/> <sup>6</sup> No serious risk of bias: The three trials by Olliaro in 2010 adequately concealed allocation and blinded participants and investigators to be considered at low risk of bias.<br/> <sup>7</sup> Downgraded by 1 for indirectness: The trials so far do not indicate a benefit with higher doses than 40 mg/kg. However, we cannot be certain that there might not be some benefit in specific settings.<br/> <sup>8</sup> Downgraded by 1 for inconsistency: One trial found a significant benefit with splitting the dose and one did not. The trials were of similar size and power. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Praziquantel 40 mg/kg for treating S. mansoni infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000528-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oxamniquine 40 mg/kg for treating S. mansoni infection</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oxamniquine 40 mg/kg for treating <i>S. mansoni</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> People with <i>S. mansoni</i> infection<br/> <b>Settings:</b> Endemic settings<br/> <b>Intervention:</b> Oxamniquine 40 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="3" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks<sup>1</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oxamniquine 40 mg/kg</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comparator</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Parasitological failure</b> </p> <p>at 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus placebo<sup>2</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 per 100</b> <br/> (66 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 8.74</b> <br/> (3.74 to 20.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 20 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>68 per 100</b> <br/> (37 to 100) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.78</b> <br/> (2.05 to 6.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190<br/> (2 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 30 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 per 100</b> <br/> (21 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> <br/> (1.15 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>268</p> <p>(4 trials)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>versus 60 mg/kg</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per 100</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 100</b> <br/> (2 to 38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.45</b> <br/> (0.09 to 2.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>317<br/> (4 trials) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is given in the footnotes. </p> <p>The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Treatment failure with oxamniquine 40 mg/kg ranged from 5% to 24% in the included studies. The risk given here is the median risk in these studies and is given for illustrative purposes.<br/> <sup>2</sup> Parasitological failure for the comparison with placebo was only reported at three months.<br/> <sup>3</sup> Downgraded by 1 for serious risk of bias: These studies did not adequately describe any methods to reduce the risk of bias.<br/> <sup>4</sup> Only two small studies have assessed this comparison. However, due to the very large effect size we have not downgraded further for indirectness or imprecision.<br/> <sup>5</sup> Downgraded by 1 for indirectness: These studies are either too few, too small, or too old to have full confidence that the results can be generalized to widespread control of <i>S. mansoni</i> today. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oxamniquine 40 mg/kg for treating S. mansoni infection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000528-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Praziquantel 40 mg/kg versus oxamniquine 40 mg/kg for treating <i>S. mansoni</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> People with <i>S. mansoni</i> infection<br/> <b>Settings:</b> Endemic settings<br/> <b>Intervention:</b> Oxamniquine 40 mg/kg </p> <p><b>Control:</b> Praziquantel 40 mg/kg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Praziquantel </b> </p> <p><b> 40 mg/kg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oxamniquine</b> </p> <p><b>40 mg/kg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parasitological failure</b> </p> <p>at 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 100</b> <br/> (7 to 61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.40</b> <br/> (0.13 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is provided in footnotes. </p> <p>The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 for serious risk of bias: This study did not adequately describe any methods to reduce the risk of bias.<br/> <sup>2</sup> Downgraded by 1 for indirectness: This single study is over 20 years old. <br/> <sup>3</sup> Downgraded by 1 for imprecision: This trial is underpowered to detect what might be important differences in effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000528-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone for treating <i>S. mansoni</i> infection</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> People with <i>S. mansoni</i> infection<br/> <b>Settings:</b> Endemic settings<br/> <b>Intervention:</b> Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) </p> <p><b>Control:</b> Praziquantel (40 mg/kg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Praziquantel </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Artesunate plus praziquantel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Parasitological failure</b> </p> <p>at 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 100</b> <br/> (17 to 55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/> (0.35 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75<br/> (1 trial) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (eg the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by 1 for serious risk of bias: This study did not adequately describe any methods to reduce the risk of bias.<br/> <sup>2</sup> Downgraded by 1 for indirectness: This is a single study and the result is not easily generalized.<br/> <sup>3</sup> Downgraded by 1 for imprecision: This trial is underpowered to detect what might be important differences in effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Artesunate (12 mg/kg) plus praziquantel (40 mg/kg) versus praziquantel (40 mg/kg) alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed search strategies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Search set</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CIDG SR^</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CENTRAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MEDLINE^^</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EMBASE^^</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>LILACS^^</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schisto* mansoni</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>SCHISTOSOMA MANSONI</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>SCHISTOSOMA MANSONI</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>SCHISTOSOMA MANSONI</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schisto$ mansoni</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCHISTOSOMIASIS MANSONI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCHISTOSOMIASIS MANSONI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SCHISTOSOMIASIS MANSONI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intestinal schistosom* ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intestinal schistosom* ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intestinal schistosom$ ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bilharzia*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bilharzia*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bilharzia$</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Esquistossomose ti, ab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schistosomicide*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schistosomicide*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schistosomicide$</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 or 3 or 4 or 5 or 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 or 3 or 4 or 5 or 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 or 2 or 3 or 4 or 5 or 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limit 7 to humans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limit 7 to humans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>^Cochrane Infectious Diseases Group Specialized Register</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>^^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (<a href="./references#CD000528-bbs2-0122" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>); Upper case: MeSH or EMTREE heading; Lower case: free text term </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Detailed search strategies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: Praziquantel versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Praziquantel dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0027" title="JaokoWG , MuchemiG , OguyaFO . Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East African Medical Journal1996;73(8):499‐501. ">Jaoko 1996 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events described as minor and transient.</p> <p>Dizziness: Praziquantel 36% versus 6% control</p> <p>Abdominal pain 35% versus 14 % control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0030" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979a BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg single dose</p> <p>40 mg/kg: 20 mg/kg twice in one day</p> <p>60 mg/kg: 20 mg/kg three times in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor, did not differ between intervention and placebo groups, but were not reported separately for the different dose schedules. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0031" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979b BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg/kg single dose</p> <p>60 mg/kg: 20 mg/kg three times in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor, did not differ between the two intervention groups, but were not reported separately for the two dosing schedules. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0036" title="OldsGR , KingCH , HewlettJ , OlvedaR , WuG , OumaJ , et al. Double‐blind placebo‐controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. Journal of Infectious Diseases1999;179(4):996‐1003. ">Olds 1999 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain: Praziquantel 80% versus 50% control</p> <p>Diarrhoea: Praziquantel 54% versus 25% control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0051" title="TweyongyereR , MawaPA , EmojongNO , MpairweH , JonesFM , DuongT , et al. Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo‐controlled trial. BMC Infectious Diseases2009;9:32. TweyongyereR , MawaPA , Ngom‐WegiS , NdibazzaJ , DuongT , VennervaldBJ , et al. Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo‐controlled trial. Journal of Infectious Diseases2008;198(12):1870‐9. ">Tweyongyere 2009 UGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor and transient. The authors pooled adverse events together over the intervention and placebo groups. Event rates were not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0007" title="BranchiniML , PedroR J de , DiasLC , DeberaldiniER . Double‐blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):315‐21. ">Branchini 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.2 to 51.6 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Dizziness: Praziquantel 46.9% (control group not reported).</p> <p>Abdominal pain: Praziquantel 24.5% versus 17.6% control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0019" title="FerrariML , CoelhoPM , AntunesCM , TavaresCA , daCunhaAS . Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bulletin of the World Health Organization2003;81(3):190‐6. ">Ferrari 2003 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180 mg/kg: 60 mg/kg once daily for three days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Events were mostly headache, dizziness, drowsiness and abdominal pain. Patients from the placebo group also reported having abdominal pain and drowsiness. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events: Praziquantel versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: praziquantel (lower dose) versus 40 mg/kg</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0030" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979a BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg single dose</p> <p>40 mg/kg: 20 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Minor adverse events, did not differ between intervention and control groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0032" title="KatzN . Clinical trials with praziquantel in schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1981;23(2):72‐8. ">Katz 1981 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Minor adverse events (lower dose first):</p> <p>Abdominal pain: 42.6% versus 44.4%</p> <p>Giddiness: 14.9% versus 26.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0041" title="OmerAH . Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung1981;31(3a):605‐8. ">Omer 1981 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Diarrhoea, vomiting, nausea and abdominal pain were commonly reported but these were transient. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events: praziquantel (lower dose) versus 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: praziquantel (higher dose) versus 40 mg/kg</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0037" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse event. Minor adverse events (highest dose first):</p> <p>Abdominal pain: 48 versus 47.9%</p> <p>Nausea: 20.4% versus 18.4%</p> <p>Dizziness: 20.4% versus 11.2%</p> <p>Headache: 14.3% versus 12.2%</p> <p>Vomiting: 11.2% versus 5.19%</p> <p>Diarrhoea: 8.2% versus 4.1%</p> <p>Rarely sleepiness was also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0038" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 MRT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One incidence of serious event was recorded in the higher dose (60 mg/kg). The rest of the events were minor. Transient dizziness, abdominal pain, diarrhoea, vomiting and headache were commonly reported (highest dose first): </p> <p>Dizziness: 77.8% versus 9.7%</p> <p>Abdominal pain:79.6% versus 71.0%</p> <p>Diarrhoea: 41.9% versus 49.5%</p> <p>Vomiting: 10.7% versus 32.3%</p> <p>Headache: 9.7% versus 14.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0039" title="OlliaroP , VaillantM , BelizarioV , LwamboN , OuldabdallahiM , PieriOS , et al. A multicentre randomized controlled trial of the efficacy and safety of single‐dose praziquantel at 40 mg/kg versus 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Neglected Tropical Diseases2011;5(6):e1165. ">Olliaro 2011 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse events (highest dose first):</p> <p>Abdominal pain: 88.9% versus 83.8%</p> <p>Diarrhoea: 47.4% versus 49.3%</p> <p>Nausea: 26.7% versus 30.9%</p> <p>Headache: 14.1% versus 9.6%</p> <p>Vomiting: 11.1% versus 16.9%</p> <p>Dizziness: 6.7% versus 9.6%</p> <p>Fever: 0% versus 1.5%.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events: praziquantel (higher dose) versus 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: praziquantel (40 mg/kg in a divided dose) versus praziquantel (40 mg/kg) single dose</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0028" title="KardamanMW , AminMA , FenwickA , CheesmondAK , DixonHG . A field trial using praziquantel (Biltricide) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan. Annals of Tropical Medicine and Parasitology1983;77(3):297‐304. ">Kardaman 1983 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg: 20 mg/kg twice in a day</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Events were transient (divided dose first): Abdominal pain: 13.5% versus 24.6% </p> <p>Vomiting: 7.6% versus 4%</p> <p>Diarrhoea: 7.6% versus 12.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0041" title="OmerAH . Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung1981;31(3a):605‐8. ">Omer 1981 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg/kg: 20 mg/kg twice in a day</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events.</p> <p>Adverse events were transient and required no additional intervention.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events: praziquantel (40 mg/kg in a divided dose) versus praziquantel (40 mg/kg) single dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events: praziquantel alternative dosing (Brazil)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0010" title="daCunhaAS , CançadoJR , deRezendeGL . Therapeutical evaluation of different dose regimens of praziquantel in schistosomiasis mansoni, based on the quantitative oogram technique. Revista do Instituto de Medicina Tropical de São Paulo1987;29(5):295‐304. ">da Cunha 1987 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180 mg/kg: 30 mg/kg twice daily for three days</p> <p>180 mg/kg: 30 mg/kg daily for six days</p> <p>120 mg/kg: 30 mg/kg twice daily for two days</p> <p>60 mg/kg: 30 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events.</p> <p>Minor and transient events (highest dose first):</p> <p>Dizziness: 65%, 15%, 45% versus 15%</p> <p>Nausea: 55%, 15, 20% versus 20%</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events: praziquantel alternative dosing (Brazil)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events: oxamniquine versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Oxamniquine dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0003" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. East African Medical Journal1984;61(8):632‐6. ">Ayele 1984 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for two days</p> <p>40 mg/kg: 10 mg/kg twice daily for two days</p> <p>30 mg/kg: 15 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor and transient.</p> <p>Dizziness: Oxamniquine (15 mg/kg BD for 2 days) 50% versus 38.9% (10 mg/kg BD for two days) versus 30% control. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0004" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. East African Medical Journal1986;63(4):291‐4. ">Ayele 1986 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for two days</p> <p>40 mg/kg: 20 mg/kg twice in one day</p> <p>30 mg/kg: 15 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All the doses were well tolerated and accepted. Dizziness was the most frequently reported complaint, but this was mild and transient. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0034" title="LambertucciJR , GrecoDB , PedrosoER , daCosta RochaMO , SalazarHM , deLimaDP . A double blind trial with oxamniquine in chronic schistosomiasis mansoni. Transactions of the Royal Society of Tropical Medicine and Hygiene1982;76(6):751‐5. ">Lambertucci 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were minor and transient.</p> <p>Dizziness: Oxamniquine 14.6% versus 2.8% control</p> <p>Nausea: Oxamniquine 14.6% versus 5.6% control.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0007" title="BranchiniML , PedroR J de , DiasLC , DeberaldiniER . Double‐blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):315‐21. ">Branchini 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events were few and minor. Dizziness: Oxamniquine 44.2% (control not reported)</p> <p>Abdominal pain: Oxamniquine 11.5% versus 17.6% control.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0019" title="FerrariML , CoelhoPM , AntunesCM , TavaresCA , daCunhaAS . Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bulletin of the World Health Organization2003;81(3):190‐6. ">Ferrari 2003 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg: 10 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events.</p> <p>Adverse events were mild, mostly headache, dizziness, drowsiness and abdominal pain. Patients from the placebo group also had abdominal pain and drowsiness. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events: oxamniquine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: oxamniquine (lower dose) versus 40 mg/kg</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0003" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. East African Medical Journal1984;61(8):632‐6. ">Ayele 1984 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg: 15 mg/kg twice in one day.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events were reported. Transient dizziness and nausea were commonly reported (lower dose first): </p> <p>Dizziness: 38.9% versus 42%</p> <p>Nausea: 22.2% versus 26.3%</p> <p>A few mild headaches and abdominal pain were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0004" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. East African Medical Journal1986;63(4):291‐4. ">Ayele 1986 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg:15 mg/kg twice in one day.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All doses were well tolerated and no serious event was recorded. Dizziness was more commonly reported, but this was transient. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0013" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976b ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg: 5 x 2 mg/kg daily for two days</p> <p>30 mg/kg: 7.5 x 2 mg/kg daily for two days.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events were recorded. Transient dizziness was more commonly reported and very rarely headache, nausea, and vomiting. Adverse events did not differ between dose. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0024" title="GuptaKK . Schistosoma mansoni treatment with oral oxamniquine in Zambia. East African Medical Journal1984;61(8):641‐4. ">Gupta 1984 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg:15 mg/kg twice in one day</p> <p>40 mg/kg: 10 mg/kg twice daily for two days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious events were reported. Adverse events were mainly dizziness and nausea, but were minor and transient (lower dose first): </p> <p>Dizziness: 20% versus 25%</p> <p>Nausea: 15% versus 30%</p> <p>A few events of vomiting, headache and abdominal pain were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0040" title="OmerAH . Oxamniquine for treating Schistosoma mansoni infection in Sudan. British Medical Journal1978;2(6131):163‐5. ">Omer 1978 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg/kg: 15 mg/kg twice in one day</p> <p>40 mg/kg: 20 mg/kg daily for 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events were recorded. Asthenia (weakness) was reported among a few receiving 40 mg/kg, but this did not require additional intervention. Transient dizziness was more commonly reported (lower dose first) </p> <p>Dizziness: 3% versus 8%</p> <p>Minor abdominal pain, headache and vomiting also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0050" title="TeesdaleCH , ChitsuloL , PughRN . Oxamniquine dosage in Malawi. East African Medical Journal1984;61(1):40‐4. ">Teesdale 1984 MWI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mg/kg single dose</p> <p>30 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Noserious adverse events were recorded. Transient dizziness, nausea and vomiting were most commonly reported. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events: oxamniquine (lower dose) versus 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0013"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: oxamniquine (higher dose) versus 40 mg/kg</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0003" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. East African Medical Journal1984;61(8):632‐6. ">Ayele 1984 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for two days</p> <p>40 mg/kg: 10 mg/kg twice daily for two days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse event was recorded. Dizziness and nausea were commonly reported but these were transient (higher dose first): </p> <p>Dizziness: 50% versus 42%</p> <p>Nausea: 11% versus 26.3%</p> <p>A few mild headaches and abdominal pain were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0004" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. East African Medical Journal1986;63(4):291‐4. ">Ayele 1986 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for 2 days</p> <p>40 mg/kg: 20 mg/kg twice in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events were recorded. Dizziness was more commonly reported, but this was transient and did not differ between dose. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0024" title="GuptaKK . Schistosoma mansoni treatment with oral oxamniquine in Zambia. East African Medical Journal1984;61(8):641‐4. ">Gupta 1984 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for two days</p> <p>40 mg/kg: 10 mg/kg twice for daily for two days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious events were reported. Transient dizziness and nausea were more commonly reported (higher dose first): </p> <p>Dizziness: 40% versus 25%</p> <p>Nausea: 25% versus 30%</p> <p>A few events of vomiting, headache and abdominal pain were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0040" title="OmerAH . Oxamniquine for treating Schistosoma mansoni infection in Sudan. British Medical Journal1978;2(6131):163‐5. ">Omer 1978 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg/kg: 15 mg/kg twice daily for 2 days</p> <p>40 mg/kg: 20 mg/kg daily for 2 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events was recorded. Transient dizziness was more commonly reported (higher dose first): </p> <p>Dizziness: 15% versus 8%</p> <p>Few minor abdominal pain, headache and vomiting were also reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0050" title="TeesdaleCH , ChitsuloL , PughRN . Oxamniquine dosage in Malawi. East African Medical Journal1984;61(1):40‐4. ">Teesdale 1984 MWI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg/kg single dose</p> <p>40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events was recorded. Transient dizziness, nausea and vomiting were most commonly reported and did not differ between dose. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Adverse events: oxamniquine (higher dose) versus 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0014"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Commonly used dosing schedule of oxamniquine and praziquantel according to location</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Location (country)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b> Dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Oxamniquine (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Praziquantel (mg/kg)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>South America</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0007" title="BranchiniML , PedroR J de , DiasLC , DeberaldiniER . Double‐blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):315‐21. ">Branchini 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0009" title="daCunhaAS , PedrosaRC . Double‐blind therapeutical evaluation based on the quantitative oogram technique, comparing praziquantel and oxamniquine in human Schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1986;28(5):337‐51. ">da Cunha 1986 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0010" title="daCunhaAS , CançadoJR , deRezendeGL . Therapeutical evaluation of different dose regimens of praziquantel in schistosomiasis mansoni, based on the quantitative oogram technique. Revista do Instituto de Medicina Tropical de São Paulo1987;29(5):295‐304. ">da Cunha 1987 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60, 120, 180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0011" title="daSilvaLC , ZeituneJM , Rosa‐EidLM , LimaDM , AntonelliRH , ChristoCH , et al. Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine. Revista do Instituto de Medicina Tropical de São Paulo1986;28(3):174‐80. ">da Silva 1986 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0018" title="FernandesP , OliveiraCC . Efficacy of two regimes of praziquantel versus oxamniquine [Estudo comparativo da eficacia do praziquantel, em dois esquemas posologicos, e da oxaminiquina no tratamento da esquistossomose mansonica]. Folha Medica1986;93(5‐6):389‐93. ">Fernandes 1986 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0019" title="FerrariML , CoelhoPM , AntunesCM , TavaresCA , daCunhaAS . Efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infection: a controlled trial. Bulletin of the World Health Organization2003;81(3):190‐6. ">Ferrari 2003 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0030" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979a BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20, 40, 60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0031" title="KatzN . Preliminary trials with praziquantel in human infections due to Schistosoma mansoni . Bulletin of the World Health Organization1979;57(5):781‐5. ">Katz 1979b BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0032" title="KatzN . Clinical trials with praziquantel in schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1981;23(2):72‐8. ">Katz 1981 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 30, 50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0033" title="KatzN , RochaRS . Double‐blind clinical trial comparing praziquantel with oxamniquine in schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):310‐4. ">Katz 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0034" title="LambertucciJR , GrecoDB , PedrosoER , daCosta RochaMO , SalazarHM , deLimaDP . A double blind trial with oxamniquine in chronic schistosomiasis mansoni. Transactions of the Royal Society of Tropical Medicine and Hygiene1982;76(6):751‐5. ">Lambertucci 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0042" title="QueirozLC , DrummondSC , MatosML , PaivaMB , BatistaTS , KansaonAZ , et al. Comparative randomised trial of high and conventional doses of praziquantel in the treatment of schistosomiasis mansoni. Memorias do Instituto Oswaldo Cruz2010;105(4):445‐8. ">Queiroz 2010 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50, 80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0043" title="Rezende GLde . Survey on the clinical results achieved in Brazil comparing praziquantel and oxamniquine in the treatment of S. mansoni schistosomiasis. Revista do Instituto de Medicina Tropical de São Paulo1985;27(6):328‐68. ">Rezende 1985 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0052" title="ZwingenbergerK , QueirozJA , PoggenseeU , AlencarJE , ValdegunasJ , EsmeraldaF , et al. Efficacy of oxamniquine, praziquantel and a combination of both drugs in schistosomiasis mansoni in Brazil. Revista do Instituto de Medicina Tropical de São Paulo1987;29(5):305‐11. ">Zwingenberger 1987 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>North Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0017" title="DoehringE , EhrichJH , VesterU , FeldmeierH , PoggenseeU , BrodehlJ . Proteinuria, hematuria, and leukocyturia in children with mixed urinary and intestinal schistosomiasis. Kidney International1985;28(3):520‐5. DoehringE , PoggenseeU , FeldmeierH . The effect of metrifonate in mixed Schistosoma haematobium and Schistosoma mansoni infections in humans. American Journal of Tropical Medicine and Hygiene1986;35(2):323‐9. FeldmeierH , GastlGA , PoggenseeU , KortmannC , DaffallaAA , PeterHH . Relationship between intensity of infection and immunomodulation in human schistosomiasis. II. NK cell activity and in vitro lymphocyte proliferation. Clinical and Experimental Immunology1985;60(2):234‐40. FeldmeierH , Nogueira‐QueirozJA , Peixoto‐QueirozMA , DoehringE , DessaintJP , deAlencarJE , et al. Detection and quantification of circulating antigen in schistosomiasis by monoclonal antibody. II. The quantification of circulating antigens in human schistosomiasis mansoni and haematobium: relationship to intensity of infection and disease status. Clinical and Experimental Immunology1986;65(2):232‐43. deJongeN , SchommerG , FeldmeierH , KrijgerFW , DafallaAA , BienzleU , et al. Mixed Schistosoma haematobium and S. mansoni infection: effect of different treatments on the serum level of circulating anodic antigen (CAA). Acta Tropica1990;48(1):25‐35. ">de Jonge 1990 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0025" title="HomeidaMM , EltomIA , SulaimanSM , AliHM , BennettJL . Tolerance of two brands of praziquantel. Lancet1989;334(8659):391. ">Homeida 1989 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0026" title="IbrahimAM . Evaluation of oxamniquine in the treatment of S. mansoni infection among Sudanese patients. East African Medical Journal1980;57(8):566‐73. ">Ibrahim 1980 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0028" title="KardamanMW , AminMA , FenwickA , CheesmondAK , DixonHG . A field trial using praziquantel (Biltricide) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan. Annals of Tropical Medicine and Parasitology1983;77(3):297‐304. ">Kardaman 1983 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0040" title="OmerAH . Oxamniquine for treating Schistosoma mansoni infection in Sudan. British Medical Journal1978;2(6131):163‐5. ">Omer 1978 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0041" title="OmerAH . Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung1981;31(3a):605‐8. ">Omer 1981 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0005" title="BarakatR , ElmorshedyH , FenwickA . Efficacy of myrrh in the treatment of human schistosomiasis mansoni. American Journal of Tropical Medicine and Hygiene2005;73(2):365‐7. ">Barakat 2005 EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0006" title="BotrosS , SayedH , El‐DusokiH , SabryH , RabieI , El‐GhannamM , et al. Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni‐infected school children and households. American Journal of Tropical Medicine and Hygiene2005;72(2):119‐23. ">Botros 2005 EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0035" title="MetwallyA , BennettJ , BotrosS , EbeidF , elattar GelD . Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. Pharmacological Research1995;31(1):53‐9. ">Metwally 1995 EGY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Egypt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>East Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0003" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in Ethiopia. East African Medical Journal1984;61(8):632‐6. ">Ayele 1984 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethiopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0004" title="AyeleT . Preliminary clinical trial of oral oxamniquine in the treatment of Schistosoma mansoni in children in Ethiopia. East African Medical Journal1986;63(4):291‐4. ">Ayele 1986 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethiopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0027" title="JaokoWG , MuchemiG , OguyaFO . Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya. East African Medical Journal1996;73(8):499‐501. ">Jaoko 1996 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kenya</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0036" title="OldsGR , KingCH , HewlettJ , OlvedaR , WuG , OumaJ , et al. Double‐blind placebo‐controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. Journal of Infectious Diseases1999;179(4):996‐1003. ">Olds 1999 KEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kenya</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0048" title="TaddeseK , ZeinZA . Comparison between the efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infections on a sugar estate in Ethiopia. Annals of Tropical Medicine and Parasitology1988;82(2):175‐80. ">Taddese 1988 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethiopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15, 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0050" title="TeesdaleCH , ChitsuloL , PughRN . Oxamniquine dosage in Malawi. East African Medical Journal1984;61(1):40‐4. ">Teesdale 1984 MWI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malawi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0044" title="RugemalilaJB , AsilaJ , ChimbeA . Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. Journal of Tropical Medicine and Hygiene1984;87(6):231‐5. ">Rugemalila 1984 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tanzania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0051" title="TweyongyereR , MawaPA , EmojongNO , MpairweH , JonesFM , DuongT , et al. Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo‐controlled trial. BMC Infectious Diseases2009;9:32. TweyongyereR , MawaPA , Ngom‐WegiS , NdibazzaJ , DuongT , VennervaldBJ , et al. Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo‐controlled trial. Journal of Infectious Diseases2008;198(12):1870‐9. ">Tweyongyere 2009 UGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uganda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>West Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0045" title="ShafeiAZ . A preliminary report on the treatment of intestinal schistosomiasis with oxamniquine. Journal of Tropical Medicine and Hygiene1979;82(1):18‐20. ">Shafei 1979 NGA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nigeria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15, 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0016" title="DeClercqD , VercruysseJ , VerleP , KongsA , DiopM . What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections?. Tropical Medicine and International Health2000;5(10):744‐6. ">De Clercq 2000 SEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0023" title="GuisseF , PolmanK , StelmaFF , MbayeA , TallaI , NiangM , et al. Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. American Journal of Tropical Medicine and Hygiene1997;56(5):511‐4. ">Guisse 1997 SEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40, 60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0046" title="StelmaFF , SallS , DaffB , SowS , NiangM , GryseelsB . Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. Journal of Infectious Diseases1997;176(1):304‐7. ">Stelma 1997 SEN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Senegal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Central Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burundi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20, 30, 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Burundi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20, 30, 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Southern Africa</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0024" title="GuptaKK . Schistosoma mansoni treatment with oral oxamniquine in Zambia. East African Medical Journal1984;61(8):641‐4. ">Gupta 1984 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zambia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0047" title="SukwaTY . A community‐based randomized trial of praziquantel to control schistosomiasis morbidity in schoolchildren in Zambia. Annals of Tropical Medicine and Parasitology1993;87(2):185‐94. ">Sukwa 1993 ZMB</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zambia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0012" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976a ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zimbabwe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15, 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0013" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976b ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zimbabwe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30, 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0014" title="deClarkeV , BlairDM , WeberMC , GarnettPA . Dose‐finding trials of oral oxamniquine in Rhodesia. South African Medical Journal1976;50(46):1867‐71. ">de Clarke 1976c ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zimbabwe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50, 60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0049" title="TaylorP , MurareHM , ManomanoK . Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium . Journal of Tropical Medicine and Hygiene1988;91(1):13‐7. ">Taylor 1988 ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zimbabwe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10, 20, 30, 40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Middle East</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0002" title="Al‐AskaAK , Al‐MoflehIA , Al‐RashedR , HafezMA , Al‐NozhaM , Abu‐AishaH , et al. Praziquantel, oxamniquine, and metrifonate in the treatment of schistosomiasis in Riyadh. Annals of Saudi Medicine1990;10(3):296‐8. ">Al Aska 1990 SAU</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saudi Arabia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Commonly used dosing schedule of oxamniquine and praziquantel according to location</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0015"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events: different oxamniquine dose versus praziquantel (40 mg/kg)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0002" title="Al‐AskaAK , Al‐MoflehIA , Al‐RashedR , HafezMA , Al‐NozhaM , Abu‐AishaH , et al. Praziquantel, oxamniquine, and metrifonate in the treatment of schistosomiasis in Riyadh. Annals of Saudi Medicine1990;10(3):296‐8. ">Al Aska 1990 SAU</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (25 mg/kg) single dose</p> <p>Praziquantel (40 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One serious adverse event (seizure) was recorded in the oxamniquine 25 mg/kg group. Transient dizziness, abdominal pain and nausea were most commonly reported (oxamniquine first): </p> <p>Dizziness: 36% versus 20%</p> <p>Abdominal pain: 25% versus 12%</p> <p>Nausea: 10% versus 8 %</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0007" title="BranchiniML , PedroR J de , DiasLC , DeberaldiniER . Double‐blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni. Revista do Instituto de Medicina Tropical de São Paulo1982;24(5):315‐21. ">Branchini 1982 BRA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (14 mg/kg) single dose</p> <p>Praziquantel (45 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were recorded. Adverse events were minor and transient. Dizziness, abdominal pain and nausea were most frequently reported (oxamniquine first): </p> <p>Dizziness: 44.2% versus 46.9%</p> <p>Abdominal pain: 3.8% versus 24.5%</p> <p>Nausea: 5.8% versus 8.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0044" title="RugemalilaJB , AsilaJ , ChimbeA . Randomized comparative trials of single doses of the newer antischistosomal drugs at Mwanza, Tanzania. I. Praziquantel and oxamniquine for the treatment of schistosomiasis mansoni. Journal of Tropical Medicine and Hygiene1984;87(6):231‐5. ">Rugemalila 1984 TZA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (15 mg/kg) single dose</p> <p>Praziquantel (40 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were recorded. Transient abdominal pain and drowsiness were commonly reported (oxamniquine first): </p> <p>Abdominal pain: 16% versus 63%</p> <p>Drowsiness: 25% versus 11%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0048" title="TaddeseK , ZeinZA . Comparison between the efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infections on a sugar estate in Ethiopia. Annals of Tropical Medicine and Parasitology1988;82(2):175‐80. ">Taddese 1988 ETH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (15 mg/kg) single dose</p> <p>Oxamniquine 30 mg/kg :15 mg/kg twice in one day</p> <p>Praziquantel (40 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One serious adverse event (seizure) was recorded with oxamniquine 30 mg/kg. Adverse events were minor and transient. Dizziness and abdominal pain were commonly reported (oxamniquine lower dose first): </p> <p>Dizziness: 22%, 16% versus 20%</p> <p>Abdominal pain: 20%, 28% versus 24%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0050" title="TeesdaleCH , ChitsuloL , PughRN . Oxamniquine dosage in Malawi. East African Medical Journal1984;61(1):40‐4. ">Teesdale 1984 MWI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (30 mg/kg) single dose</p> <p>Oxamniquine (40 mg/kg) single dose</p> <p>Oxamniquine (50 mg/kg): 25 mg/kg twice in one day</p> <p>Praziquantel (40 mg/kg) single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious adverse events were recorded. Transient dizziness was commonly reported among participants receiving oxamniquine. There was no difference in events between oxamniquine 30, 40 and 50 mg/kg (oxamniquine lower dose first): </p> <p>Dizziness: 30.8%, 29.2%, 30.8% versus 8.3%</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Adverse events: different oxamniquine dose versus praziquantel (40 mg/kg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0016"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse events: oxamniquine plus praziquantel versus oxamniquine plus praziquantel</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> No. of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Remarks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000528-bbs2-0008" title="CreaseyAM , TaylorP , ThomasJE . Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean schoolchildren. Central African Journal of Medicine1986;32(7):165‐7. ">Creasey 1986 ZWE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxamniquine (4 mg/kg) plus praziquantel (8 mg/kg) versus oxamniquine (10 mg/kg) plus praziquantel (20 mg/kg) </p> <p>Oxamniquine (7.5 mg/kg) plus</p> <p>praziquantel (15 mg/kg) versus</p> <p>praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No serious adverse events. Adverse events were minor and did not differ between combinations. One child reported dizziness five minutes after treatment but required no further treatment and was well the following day. About 70% of children reported abdominal discomfort but these were transient and had resolved the following day. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Adverse events: oxamniquine plus praziquantel versus oxamniquine plus praziquantel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0017"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Non‐randomized exploratory analysis of age (praziquantel)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Dose (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Time point (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Number failed/number examined  (%) <sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Children (&lt;20 years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adults (≥20 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48/109 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/61 (43)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49/100 (49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/54 (30)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61/109 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/58 (33)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60/101 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/59 (36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/93 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/48 (4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/104 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/65 (18)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/91 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/40 (10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/98 (38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/66 (15)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/94 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/46 (13)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/94 (43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/61 (31)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/91 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/44 (20)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73/92 (79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/51 (37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/94 (23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/42 (12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/81 (22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/54 (4)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/87 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/32 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/83 (31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/54 (20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/92 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/37 (11)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0022" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989c BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/76 (30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/51 (20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0021" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989b BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/84 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/38 (26)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Number failed/number examined (%) presented for the praziquantel treatment group of each study that presents data for adults and children separately. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Non‐randomized exploratory analysis of age (praziquantel)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000528-tbl-0018"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Non‐randomized exploratory analysis of age (oxamniquine)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b> Dose (mg/kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Time point (month)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Number failed/number examined (%) <sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Children (&lt; 20 years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adults (≥ 20 years)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/41 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/55 (6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/57 (60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/95 (17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> 6/41 (15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/55 (7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/56 (54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/102 (22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/41 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/55 (16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/49 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/86 (23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/41 (93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/83 (24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/42 (38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/76 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/46 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/77 (10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/41 (54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/62 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/39 (62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/67 (15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/43 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/57 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/49 (19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/67 (3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/57 (5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/51 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/65 (8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/31 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/57 (9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/42 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/62 (18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0020" title="GryseelsB , NkulikyinkaL . Two‐year follow‐up of Schistosoma mansoni infection and morbidity after treatment with different regimens of oxamniquine and praziquantel. Transactions of the Royal Society of Tropical Medicine and Hygiene1989;83(2):219‐28. ">Gryseels 1989a BDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/38 (66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/60 (18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/42 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/58 (0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/42 (24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/58 (2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000528-bbs2-0001" title="Abdel RahimIM , HaridiAA , Abdel‐HameedAA . Field study of different oxamniquine dose for Schistosoma mansoni in Gezira, Sudan. Journal of Tropical Medicine and Hygiene1988;91(3):131‐7. Abdel‐RahimIM , HaridiAA , Abdel‐HameedAA . A field evaluation of three dose levels of oxamniquine in Gezira‐ Sudan. East African Medical Journal1988;65(11):771‐7. ">Abdel Rahim 1988 SDN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/42 (38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/58 (2)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>1</sup>Number failed/number examined (%) presented for the oxamniquine treatment group of each study that presents data for adults and children separately. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Non‐randomized exploratory analysis of age (oxamniquine)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/full#CD000528-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Praziquantel versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 40 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [1.03, 9.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 20 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 40 mg/kg in two divided doses on the same day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 60 mg/kg in 3 divided doses 3 hours apart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 60 mg/kg daily for 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 20 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 40 mg/kg in two divided doses on the same day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 60 mg/kg in 3 divided doses 3 hours apart</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Praziquantel versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Praziquantel (lower dose) versus praziquantel 40 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Praziquantel 20 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.64, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Praziquantel 30 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.15, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Praziquantel 20 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [1.66, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Praziquantel 30 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.10, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six to 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Praziquantel 20 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.54 [1.35, 4.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Praziquantel 30 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.19, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Praziquantel (lower dose) versus praziquantel 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Resolution of abdominal pain: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Resolution of abdominal pain: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.55, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.53, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.52, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.35, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.55, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Resolution of diarrhoea: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Resolution of diarrhoea: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.70, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.82, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.76, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.77, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.69, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Resolution of blood in stool: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Resolution of blood in stool: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.87, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.79, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.78, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Resolution of hepatomegaly: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Resolution of hepatomegaly: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.69, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Resolution of splenomegaly: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Resolution of splenomegaly: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.66, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.76, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.72, 1.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Praziquantel lower dose (20 and 30 mg/kg) versus praziquantel 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Praziquantel (higher dose) versus praziquantel 40 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Praziquantel 60 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Praziquantel 50 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Praziquantel 60 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six to 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Praziquantel 60 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Praziquantel (higher dose) versus praziquantel 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.13, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.18, 0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Praziquantel 40 mg/kg divided dose versus praziquantel 40 mg/kg single dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Praziquantel alternative dosing (Brazil)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Praziquantel 30 mg/kg x 2 daily for 2 days versus praziquantel 30 mg/kg x 2 in one day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Praziquantel 30 mg/kg x 2 daily for 3 days versus praziquantel 30 mg/kg x 2 in one day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Praziquantel 30 mg/kg x 1 daily for 6 days versus 30 mg/kg x 2 in one day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Praziquantel 20 mg/kg x 3, 4 hours apart versus praziquantel 50 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Praziquantel 40 mg/kg x 2, 1 hour apart versus praziquantel 50 mg/kg single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Percent egg reduction at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Percent egg reduction at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Praziquantel alternative dosing (Brazil)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Oxamniquine versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at three to four months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 30 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.34 [2.47, 7.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.74 [3.74, 20.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 60 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.38 [5.79, 64.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at six to 10 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 20 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [2.53, 5.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Percent egg reduction at three to four months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxamniquine (40 mg/kg) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oxamniquine (20 to 30 mg/kg) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Oxamniquine (60 mg/kg) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Oxamniquine versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Oxamniquine (lower dose) versus oxamniquine 40 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oxamniquine 20 mg/kg versus oxamniquine 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.78 [2.05, 6.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oxamniquine 30 mg/kg versus oxamniquine 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.15, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three to four months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oxamniquine 20 mg/kg versus oxamniquine 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.40, 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Oxamniquine 30 mg/kg versus oxamniquine 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.10, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxamniquine 20 mg/kg versus oxamniquine 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.48, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oxamniquine 30 mg/kg versus oxamniquine 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.71, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Parasitological failure at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oxamniquine 20 mg/kg versus oxamniquine 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.32, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Oxamniquine 30 mg/kg versus oxamniquine 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.67, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Percent egg reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Three to four months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Oxamniquine (lower dose) versus oxamniquine 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Resolution of abdominal pain: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Resolution of abdominal pain: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Resolution of diarrhoea: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Resolution of diarrhoea: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Resolution of blood in stool: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Resolution of blood in stool: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Resolution of hepatomegaly: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Resolution of hepatomegaly: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Resolution of splenomegaly: 20 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Resolution of splenomegaly: 30 mg/kg versus 40 mg/kg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Oxamniquine lower dose (20 and 30 mg/kg) versus oxamniquine 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Oxamniquine (higher dose) versus oxamniquine 40 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oxamniquine (50 mg/kg) versus oxamniquine (40 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.21, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oxamniquine (60 mg/kg) versus oxamniquine (40 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.09, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three to four months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oxamniquine (50 mg/kg) versus oxamniquine (40 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.25, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Oxamniquine (60 mg/kg) versus oxamniquine (40 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.12, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxamniquine (60 mg/kg) versus oxamniquine (40 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.12, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Three to four months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Oxamniquine (higher dose) versus oxamniquine 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Oxamniquine (lower dose) 15 to 20 mg/kg versus oxamniquine 30 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.14, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Three to four months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [1.40, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.86, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 6 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.02, 2.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Oxamniquine (lower dose) 15 to 20 mg/kg versus oxamniquine 30 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Oxamniquine (higher dose) versus oxamniquine 30 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oxamniquine 50 mg/kg versus oxamniquine 30 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.15, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oxamniquine 60 mg/kg versus oxamniquine 30 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three to four months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oxamniquine 50 mg/kg versus oxamniquine 30 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.44, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Oxamniquine 60 mg/kg versus oxamniquine 30 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.07, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxamniquine (60 mg/kg) versus oxamniquine (30 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.06, 0.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Oxamniquine (higher dose) versus oxamniquine 30 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Oxamniquine versus praziquantel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oxamniquine 10 to 20 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>232</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.08, 14.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oxamniquine 30 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.35, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.13, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Oxamniquine 50 to 60 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.16, 4.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oxamniquine (10 to 20 mg/kg) versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.42 [1.10, 10.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Oxamniquine (25 to 30 mg/kg) versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.40, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Oxamniquine 40 mg/kg versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.14, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Oxamniquine (50 to 60 mg/kg) versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.13, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxamniquine (10 to 20 mg/kg) versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.70, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oxamniquine (25 to 30 mg/kg) versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.22, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Oxamniquine (50 to 60 mg/kg) versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [1.11, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Oxamniquine (15 to 20 mg/kg) versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.83, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Parasitological failure at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oxamniquine (10 to 20 mg/kg) versus praziquantel 40 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Percent egg reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Oxamniquine versus praziquantel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Myrrh (Mirazid) 300 mg once daily for three days versus praziquantel 40 mg/kg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at three to six weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Percent egg reduction three to six weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Myrrh (Mirazid) 300 mg once daily for three days versus praziquantel 40 mg/kg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Praziquantel (40 mg/kg) plus artesunate (12 mg/kg total dose) versus praziquantel (40 mg/kg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at three months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Praziquantel (20 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (40 mg/kg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Praziquantel (8 mg/kg) plus oxamniquine (4 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000528-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Parasitological failure at one month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Parasitological failure at three months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Parasitological failure at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percent egg reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 One month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Three months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Six months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Praziquantel (15 mg/kg) plus oxamniquine (7.5 mg/kg) versus praziquantel (20 mg/kg) plus oxamniquine (10 mg/kg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000528.pub2/references#CD000528-tbl-0036">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000528.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000528-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000528-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000528-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="pt#CD000528-note-0002">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD000528-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000528\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000528\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000528\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000528\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000528\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000528.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000528.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000528.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000528.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000528.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717341304"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000528.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717341309"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000528.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db584d9909365',t:'MTc0MDcxNzM0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 